[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 230
1. Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, Qin Y, Sun Z, Zheng X: miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer; 2010;10:354
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells.
  • BACKGROUND: In recent years, some miRNAs have been reported to be connected closely with the development of human hepatocellular carcinoma.
  • METHODS: The expression profiles of miR-183 were compared between HCC tissues and adjacent normal liver tissues using qRT-PCR method.
  • Finally, the functional effect of miR-183 in hepatoma cells was examined.
  • RESULTS: Among the 25 HCC samples analyzed, microRNA-183 was significantly up-regulated (twofold to 367-fold) in 17 samples compared with the matching nontumoral liver tissues.
  • Programmed cell death 4 (PDCD4) was identified as the target gene of miR-183.
  • [MeSH-major] Apoptosis. Apoptosis Regulatory Proteins / metabolism. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. MicroRNAs / physiology. RNA-Binding Proteins / metabolism. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. DNA Primers / chemistry. Down-Regulation. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Liver / metabolism. Liver / pathology. Luciferases / metabolism. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):26-37 [12482958.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1915-22 [19276261.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6034-41 [16024603.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1573-6 [16081698.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1519-24 [16141061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] J Cell Biochem. 2006 Oct 15;99(3):671-8 [16924677.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6101-12 [16682950.001]
  • [Cites] Semin Liver Dis. 2007 Feb;27(1):55-76 [17295177.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6092-9 [17616664.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):647-58 [17681183.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1026-33 [17991735.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):664-73 [18245465.001]
  • [Cites] Cell Res. 2008 Mar;18(3):350-9 [18270520.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Hepatology. 2008 Apr;47(4):1223-32 [18307259.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):257-69 [18555017.001]
  • [Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4820-9 [18427550.001]
  • [Cites] Nucleic Acids Res. 2008 Sep;36(16):5391-404 [18701644.001]
  • [Cites] FEBS Lett. 2008 Oct 29;582(25-26):3663-8 [18840437.001]
  • [Cites] Cytogenet Cell Genet. 1999;87(1-2):113-4 [10640828.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Int J Oncol. 2009 Apr;34(4):1069-75 [19287964.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2170-5 [9605762.001]
  • (PMID = 20602797.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DNA Primers; 0 / MIRN183 microRNA, human; 0 / MicroRNAs; 0 / PDCD4 protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / RNA-Binding Proteins; 0 / Transforming Growth Factor beta1; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2909210
  •  go-up   go-down


2. Baertschiger RM, Serre-Beinier V, Morel P, Bosco D, Peyrou M, Clément S, Sgroi A, Kaelin A, Buhler LH, Gonelle-Gispert C: Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver. PLoS One; 2009;4(8):e6657
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver.
  • As differentiation potential might be dependent of donor age, we studied MSC derived from adult and pediatric human bone marrow and their potential to differentiate into hepatocytes or myofibroblasts in vitro and in vivo.
  • Following characterization, expanded adult and pediatric MSC were co-cultured with a human hepatoma cell line, Huh-7, in a hepatogenic differentiation medium containing Hepatocyte growth factor, Fibroblast growth factor 4 and oncostatin M.
  • In vivo, MSC were transplanted into spleen or liver of NOD/SCID mice undergoing partial hepatectomy and retrorsine treatment.
  • In vitro, adult and pediatric MSC expressed characteristic surface antigens of MSC.
  • Expansion capacity of pediatric MSC was significantly higher when compared to adult MSC.
  • In co-culture with Huh-7 cells in hepatogenic differentiation medium, albumin expression was more frequently detected in pediatric MSC (5/8 experiments) when compared to adult MSC (2/10 experiments).
  • However, in such condition pediatric MSC expressed alpha smooth muscle more strongly than adult MSC.
  • Stable engraftment in the liver was not achieved after intrasplenic injection of pediatric or adult MSC.
  • After intrahepatic injection, MSC permanently remained in liver tissue, kept a mesenchymal morphology and expressed vimentin and alpha smooth muscle actin, but no hepatic markers.
  • Further, MSC localization merges with collagen deposition in transplanted liver and no difference was observed using adult or pediatric MSC.
  • In conclusion, when transplanted into an injured or regenerating liver, MSC differentiated into myofibroblasts with development of fibrous tissue, regardless of donor age.
  • These results indicate that MSC in certain circumstances might be harmful due to their fibrogenic potential and this should be considered before potential use of MSC for cell therapy.
  • [MeSH-major] Liver / pathology. Liver Cirrhosis / pathology. Mesoderm / cytology. Stromal Cells / cytology
  • [MeSH-minor] Actins / metabolism. Animals. Blotting, Western. Cell Differentiation. Collagen / metabolism. Humans. Immunohistochemistry. Mice. Mice, Inbred NOD. Mice, SCID. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1441-6 [9037072.001]
  • [Cites] J Cell Biol. 1993 Jul;122(1):103-11 [8314838.001]
  • [Cites] Nat Med. 1999 Mar;5(3):309-13 [10086387.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1275-84 [15562440.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 4;328(1):258-64 [15670778.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 20;330(4):1153-61 [15823564.001]
  • [Cites] Blood. 2005 Jul 15;106(2):756-63 [15817682.001]
  • [Cites] World J Gastroenterol. 2005 Aug 7;11(29):4497-504 [16052678.001]
  • [Cites] Cytotherapy. 2005;7(5):393-5 [16236628.001]
  • [Cites] J Hepatol. 2005 Dec;43(6):1031-7 [16169114.001]
  • [Cites] J Hepatol. 2006 Apr;44(4):742-8 [16469408.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):928-35 [16306150.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1807-21 [16697743.001]
  • [Cites] Transplantation. 2006 May 27;81(10):1390-7 [16732175.001]
  • [Cites] Aging Cell. 2006 Jun;5(3):213-24 [16842494.001]
  • [Cites] Stem Cells. 2007 Jan;25(1):220-7 [16960135.001]
  • [Cites] Cell Tissue Res. 2007 Mar;327(3):463-70 [17093919.001]
  • [Cites] Stem Cells. 2007 Mar;25(3):639-45 [17110617.001]
  • [Cites] Stem Cells. 2007 Mar;25(3):646-54 [17124009.001]
  • [Cites] Gut. 2007 Mar;56(3):405-15 [16928726.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Apr;13(4):412-22 [17382248.001]
  • [Cites] Hepatology. 2007 Jul;46(1):219-28 [17596885.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9142-9 [17909019.001]
  • [Cites] Protein Sci. 2007 Nov;16(11):2531-41 [17905828.001]
  • [Cites] Stem Cells. 2007 Nov;25(11):2739-49 [17656645.001]
  • [Cites] Mol Ther. 2008 Jan;16(1):187-93 [17955022.001]
  • [Cites] Nucleic Acids Res. 2007;35(22):7557-65 [18160407.001]
  • [Cites] Gut. 2008 Feb;57(2):223-31 [17639088.001]
  • [Cites] Mech Ageing Dev. 2008 Mar;129(3):163-73 [18241911.001]
  • [Cites] Gastroenterology. 2008 Mar;134(3):833-48 [18243183.001]
  • [Cites] Stem Cells. 2008 Mar;26(3):789-97 [18065393.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):13108-15 [18332148.001]
  • [Cites] Stem Cells. 2008 May;26(5):1307-14 [18308943.001]
  • [Cites] J Viral Hepat. 2008 Jul;15(7):508-14 [18397225.001]
  • [Cites] Pancreas. 2008 Jul;37(1):75-84 [18580448.001]
  • [Cites] Hepatology. 2000 Jul;32(1):11-6 [10869283.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):257 [10917519.001]
  • [Cites] N Engl J Med. 2002 Mar 7;346(10):738-46 [11882729.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Nov;16(11):1244-53 [11903743.001]
  • [Cites] J Clin Invest. 2002 May;109(10):1291-302 [12021244.001]
  • [Cites] J Invest Surg. 2003 Mar-Apr;16(2):99-102 [12746193.001]
  • [Cites] J Cell Physiol. 2004 Jan;198(1):110-8 [14584050.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):955-63 [15057733.001]
  • [Cites] Stem Cells. 2004;22(5):675-82 [15342932.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Exp Hematol. 1974;2(2):83-92 [4455512.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Apr;80(8):2361-4 [6340120.001]
  • [Cites] J Cell Biol. 1986 Dec;103(6 Pt 2):2787-96 [3539945.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):319-29 [9665494.001]
  • (PMID = 19684854.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC2722022
  •  go-up   go-down


3. Xu MH, Qu Q, Zhang GY: [H.pylori in patients with cirrhosis and liver cirrhosis with hepatocellular carcinoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Oct;32(5):917-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [H.pylori in patients with cirrhosis and liver cirrhosis with hepatocellular carcinoma].
  • OBJECTIVE: To understand the prevalence of H.pylori infection in patients with cirrhosis, and liver cirrhosis with hepatocellular carcinoma(HCC), and to investigate the relationship between H.pylori infection and liver cirrhosis, and liver cirrhosis with hepatocellular carcinoma in patients.
  • METHODS: Serum anti-H.pylori antibodies IgG (HpIgG) was measured by dot immunogold filtration assay (DIGFA) in 101 liver cirrhosis and 42 liver cirrhosis with hepatoma patients and alpha-fetopro-tei(AFP)was determined by chemiluminescence.
  • RESULTS: HpIgG seroprevalence was 42.57% (43/101) in the liver cirrhosis patients, and 69.05% (29/42) in the liver cirrhosis with the HCC patients.
  • HpIgG seropositivity in the liver cirrhosis with the HCC patients was higher than in those without HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / microbiology. Helicobacter Infections / complications. Helicobacter pylori / isolation & purification. Liver Cirrhosis / microbiology. Liver Neoplasms / microbiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Bacterial / blood. Female. Humans. Male. Middle Aged. Risk Factors. Seroepidemiologic Studies. Young Adult. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18007096.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / alpha-Fetoproteins
  •  go-up   go-down


Advertisement
4. Soon JL, Jeyaraj PR, Agasthian T: Thoracic complications of radiofrequency ablation of recurrent hepatoma. Ann Acad Med Singapore; 2008 Jan;37(1):75-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic complications of radiofrequency ablation of recurrent hepatoma.
  • INTRODUCTION: Radiofrequency ablation (RFA) for unresectable primary or secondary hepatic malignancies have gained widespread availability and acceptance over the past 5 years.
  • CLINICAL PICTURE: We report a patient with symptomatic right pleural effusion due to a diaphragmatic fistula and another with biliptysis post-RFA, for recurrent hepatoma.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / adverse effects. Diaphragm / physiopathology. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Fistula / etiology. Humans. Male. Pleural Effusion / etiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265903.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


5. Chen YY, Chiang J, Chen YJ, Chen KT, Yang RS, Lin JG: Cycling and Tai Chi Chuan exercises exert greater immunomodulatory effect on surface antigen expression of human hepatitis B virus. Chin Med J (Engl); 2008 Nov 5;121(21):2172-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Human peripheral blood mononuclear cells from competitive cyclists and sedentary controls were stimulated by phytohemagglutinin (PHA) to prepare conditioned medium (MNC-CM) for the assessment of inhibitory effects on hepatitis B surface antigen (HBsAg) expression in human hepatoma Hep3B cells.
  • [MeSH-minor] Adult. Humans. Interferon-gamma / physiology. Male. Oxygen Consumption. Tumor Necrosis Factor-alpha / physiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080180.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


6. Wu HB, Lee MC, Lai KH, Ho ST, Sun WZ, Wong JO, Ger LP: Physicians' knowledge about pharmacological management of cancer pain--with special reference on their prescribing responses to simulated patients with cancer pain. Acta Anaesthesiol Taiwan; 2006 Jun;44(2):61-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, physicians' knowledge deficits in the practice subscale, but not the principle subscale, correlated with their correct prescription of opioids to the simulated hepatoma cases.
  • [MeSH-minor] Adult. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Female. Humans. Male. Meperidine / therapeutic use. Middle Aged. Patient Simulation. Practice Patterns, Physicians'

  • Hazardous Substances Data Bank. MEPERIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Anaesthesiol Taiwan. 2006 Jun;44(2):59-60 [16845910.001]
  • (PMID = 16845911.001).
  • [ISSN] 1875-4597
  • [Journal-full-title] Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists
  • [ISO-abbreviation] Acta Anaesthesiol Taiwan
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Analgesics; 0 / Anti-Inflammatory Agents, Non-Steroidal; 9E338QE28F / Meperidine
  •  go-up   go-down


7. Wang GL, Wang MY, Wei WB: [Clinical features and treatment of choroidal metastasis]. Zhonghua Yan Ke Za Zhi; 2009 Mar;45(3):229-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary tumours were found in 40 cases (81.6%) (surgical excision in 25 cases), consisting of breast carcinoma in 16 cases (32.7%), lung carcinoma in 14 cases (28.6%), hepatoma and cholangiocarcinoma in 3 cases, colon and stomach carcinomas in 3 cases, gynecologic appendix carcinoma (including 1 case of ovarian mucous cyst adenocarcinoma) in 2 cases, nasopharyngeal adenocarcinoma in 1 case, vertebra tumor in 1 case, undetected in 5 cases (10.2%) and under detection in 4 cases (8.2%).
  • The primary tumor can be found in 80% of cases.
  • The most common primary cancer is breast carcinoma, followed by lung carcinoma.
  • These two cancers account for 75% of primary tumors.
  • [MeSH-minor] Adult. Aged. Female. Fluorescein Angiography. Fundus Oculi. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575917.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C: The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact; 2007 May 20;168(1):66-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
  • Although they have several important limitations primary human hepatocytes still represent the in vitro gold standard model for xenobiotic metabolism and toxicity studies.
  • The large use of human liver cell lines either from tumoral origin or obtained by oncogenic immortalisation is prevented by the loss of various liver-specific functions, especially many cytochrome P450 (CYP)-related enzyme activities.
  • We review here recent results obtained with a new human hepatoma cell line, named HepaRG, derived from a human hepatocellular carcinoma.
  • Moreover contrary to other human hepatoma cell lines including HepG2 cells, HepaRG cells express various CYPs (CYP1A2, 2B6, 2C9, 2E1, 3A4) and the nuclear receptors constitutive androstane receptor (CAR) and pregnane X receptor (PXR) at levels comparable to those found in cultured primary human hepatocytes.
  • They also express various other functions such phase 2 enzymes, apical and canalicular ABC transporters and basolateral solute carrier transporters, albumin, haptoglobin as well as aldolase B that is a specific marker of adult hepatocytes.
  • HepaRG cells could represent a surrogate to primary human hepatocytes for xenobiotic metabolism and toxicity studies and even more, a unique model system for analysing genotoxic compounds.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Models, Biological. Xenobiotics / toxicity
  • [MeSH-minor] Aflatoxin B1 / poisoning. Biomarkers / metabolism. Cell Differentiation. Cell Line, Tumor. Cytochrome P-450 Enzyme System / genetics. Cytochrome P-450 Enzyme System / metabolism. Female. Hepatocytes / cytology. Hepatocytes / drug effects. Hepatocytes / metabolism. Humans. Inhibitory Concentration 50. Metabolic Detoxication, Phase I. Metabolic Detoxication, Phase II. RNA, Messenger / analysis. Receptors, Cytoplasmic and Nuclear / genetics. Receptors, Cytoplasmic and Nuclear / metabolism. Receptors, Steroid / genetics. Receptors, Steroid / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. AFLATOXIN B1 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241619.001).
  • [ISSN] 0009-2797
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / Transcription Factors; 0 / Xenobiotics; 0 / constitutive androstane receptor; 0 / pregnane X receptor; 9035-51-2 / Cytochrome P-450 Enzyme System; 9N2N2Y55MH / Aflatoxin B1
  • [Number-of-references] 23
  •  go-up   go-down


9. Zhang X, Zhou L, Chen B, Hu S, Wachtel MS, Frezza EE: Microwave ablation with cooled-tip electrode for liver cancer: an analysis of 160 cases. Minim Invasive Ther Allied Technol; 2008;17(5):303-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microwave ablation with cooled-tip electrode for liver cancer: an analysis of 160 cases.
  • A novel microwave electrode with a cooled tip (FORSEA MTC-3 type, China) was devised to better enable microwave ablation of liver cancers.
  • The records of 160 patients (97 with hepatoma, 63 with metastatic cancer of the liver) who had undergone microwave ablation with this new device were reviewed.
  • For patients with hepatoma, serum alpha-fetoprotein (AFP) levels were evaluated pre-operatively and, if elevated, post-operatively.
  • Twenty-five patients with hepatoma had elevated AFP (104.2+/-22.5 ng/ml), which, after microwave ablation, recovered to normal or almost normal (24.6+/-3.6 ng/ml) (t = 2.1, p<0.05).
  • The tool may greatly expand the fraction of patients with liver cancer who might be candidates for microwave ablation.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery. Microwaves
  • [MeSH-minor] Adolescent. Adult. Aged. Contrast Media / administration & dosage. Electrodes. Female. Follow-Up Studies. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Recurrence, Local. Postoperative Complications / etiology. Postoperative Complications / therapy. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed / methods. Treatment Outcome. Young Adult. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Minim Invasive Ther Allied Technol. 2009;18(6):373 [19929303.001]
  • (PMID = 18942003.001).
  • [ISSN] 1365-2931
  • [Journal-full-title] Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  • [ISO-abbreviation] Minim Invasive Ther Allied Technol
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / alpha-Fetoproteins
  •  go-up   go-down


10. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis


11. Guguen-Guillouzo C, Guillouzo A: General review on in vitro hepatocyte models and their applications. Methods Mol Biol; 2010;640:1-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary hepatocytes appear as the closest model for the liver in vivo.
  • Hepatoma cell lines appear as an alternative but only the HepaRG cell line exhibits various functions, including major cytochrome P450 activities, at levels close to those found in primary hepatocytes.
  • In vitro hepatocyte models have brought a substantial contribution to the understanding of the biochemistry, physiology, and cell biology of the normal and diseased liver and in various application domains such as xenobiotic metabolism and toxicity, virology, parasitology, and more generally cell therapies.
  • In the future, new well-differentiated hepatocyte cell lines derived from tumors or from either embryonic or adult stem cells might be expected and although hepatocytes will continue to be used in various fields, these in vitro liver models should allow marked advances, especially in cell-based therapies and predictive and mechanistic hepatotoxicity of new drugs and other chemicals.
  • All models will benefit from new developments in throughput screening based on cell chips coupled with high-content imaging and in toxicogenomics technologies.
  • [MeSH-minor] Animals. Cell Culture Techniques / methods. Humans. Models, Biological. Toxicogenetics. Xenobiotics / metabolism. Xenobiotics / toxicity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645044.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Xenobiotics
  •  go-up   go-down


12. Zhang GQ, Wang HB, Gao P, Fang CH, Chen GH: [Relationship of extrahepatic metastasis of primary hepatocellular carcinoma between circulative tumor cells in the blood of hepatoma patients]. Zhonghua Wai Ke Za Zhi; 2009 Dec 15;47(24):1857-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship of extrahepatic metastasis of primary hepatocellular carcinoma between circulative tumor cells in the blood of hepatoma patients].
  • OBJECTIVE: To study the relationship between extrahepatic metastasis of primary hepatocellular carcinoma and circulative tumor cells in the blood of hepatoma patients.
  • METHODS: The immunomagnetic bead technique was employed to enrich and separate the hepatoma cells in the peripheral blood of preoperative and postoperative hepatoma patients.
  • The relationship between postoperative extrahepatic metastasis and hepatoma cells in peripheral blood cancer cells were analyzed.
  • The circulative tumor cells in the peripheral blood of hepatoma patients were enriched and separated by immunomagnetic bead technique.
  • They were identified as hepatoma cells by AFP immunohistochemistry.
  • Among 30 cases of hepatoma patients, the positive rate of hepatoma cells in the peripheral blood of preoperation and postoperation were 53.3% and 83.3% respectively.
  • CONCLUSIONS: Extrahepatic metastasis of primary hepatocellular carcinoma is obviously correlated to the positive tumor cells and the concentration in the peripheral blood of preoperative patients.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193401.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


13. Kim S, Dere E, Burgoon LD, Chang CC, Zacharewski TR: Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci; 2009 Nov;112(1):229-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells.
  • Time course and dose-response studies were conducted in HL1-1 cells, a human liver cell line with stem cell-like characteristics, to assess the differential gene expression elicited by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) compared with other established models.
  • Comparative analysis of HL1-1 differential gene expression to human HepG2 data identified 74 genes with comparable temporal expression profiles including 12 putative primary responses.
  • Furthermore, comparative analysis of HL1-1 cells with mouse Hepa1c1c7 hepatoma cell lines and C57BL/6 hepatic tissue identified 18 and 32 commonly regulated orthologous genes, respectively, with functions associated with signal transduction, transcriptional regulation, metabolism and transport.
  • [MeSH-major] Gene Expression Profiling. Liver / drug effects. Receptors, Aryl Hydrocarbon / physiology. Stem Cells / drug effects. Tetrachlorodibenzodioxin / toxicity

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1129-42 [11007951.001]
  • [Cites] Regul Toxicol Pharmacol. 2000 Aug;32(1):56-67 [11029269.001]
  • [Cites] Toxicol Sci. 2001 Jan;59(1):17-36 [11134541.001]
  • [Cites] Toxicol Sci. 2001 Sep;63(1):65-73 [11509745.001]
  • [Cites] Toxicol In Vitro. 2001 Dec;15(6):741-53 [11698176.001]
  • [Cites] Toxicol Lett. 2002 Feb 28;127(1-3):153-60 [12052653.001]
  • [Cites] Nat Rev Genet. 2002 Aug;3(8):579-88 [12154381.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):386-402 [12657743.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):207-8 [12700407.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jul;2(7):542-53 [12815380.001]
  • [Cites] Nature. 2003 Aug 21;424(6951):870-2 [12931155.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):361-9 [15093282.001]
  • [Cites] Mutat Res. 2004 May 18;549(1-2):79-99 [15120964.001]
  • [Cites] Toxicol Sci. 2004 Jun;79(2):214-23 [15014205.001]
  • [Cites] Nucleic Acids Res. 2004;32(15):4512-23 [15328365.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 27;321(3):707-15 [15358164.001]
  • [Cites] J Biopharm Stat. 2004 Aug;14(3):647-70 [15468757.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1177-82 [9214600.001]
  • [Cites] Environ Health Perspect. 1998 Apr;106 Suppl 2:755-60 [9599727.001]
  • [Cites] Bull Environ Contam Toxicol. 1998 Nov;61(5):557-68 [9841714.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):1078-83 [15513988.001]
  • [Cites] Toxicol Sci. 2005 Jun;85(2):1048-63 [15800033.001]
  • [Cites] Toxicol Sci. 2005 Oct;87(2):508-19 [16049271.001]
  • [Cites] Toxicol Sci. 2006 Apr;90(2):558-68 [16403854.001]
  • [Cites] BMC Genomics. 2006;7:80 [16611356.001]
  • [Cites] BMC Genomics. 2006;7:217 [16934159.001]
  • [Cites] Mol Nutr Food Res. 2006 Oct;50(10):897-907 [16977593.001]
  • [Cites] Toxicol Sci. 2006 Dec;94(2):398-416 [16960034.001]
  • [Cites] Toxicology. 2007 Feb 28;231(1):1-10 [17208344.001]
  • [Cites] Pharmacogenomics. 2007 Mar;8(3):287-91 [17324117.001]
  • [Cites] Toxicol Sci. 2007 Jul;98(1):5-38 [17569696.001]
  • [Cites] Biochem Pharmacol. 2007 Aug 1;74(3):496-503 [17568565.001]
  • [Cites] Toxicol Sci. 2008 Mar;102(1):61-75 [18042819.001]
  • [Cites] Mol Pharmacol. 2008 Mar;73(3):769-77 [18089838.001]
  • [Cites] Toxicol Sci. 2008 Jun;103(2):285-97 [18343893.001]
  • (PMID = 19684285.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Aryl Hydrocarbon; DO80M48B6O / Tetrachlorodibenzodioxin
  • [Other-IDs] NLM/ PMC2769060
  •  go-up   go-down


14. Grozdanov PN, Petkov PM, Karagyozov LK, Dabeva MD: Expression and localization of PCSK9 in rat hepatic cells. Biochem Cell Biol; 2006 Feb;84(1):80-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the expression and subcellular localization of PCSK9 in fetal and adult rat tissues associated with cholesterol homeostasis using quantitative reverse transcriptase--PCR, Western blot analysis, subcellular fractionation, and confocal immunofluorescent microscopy.
  • PCSK9 mRNA is most abundant in yolk sac and fetal liver, but the highest expression of the protein was found in differentiated hepatoma FAO-1 cell line, which also shows the highest expression of LDLR.
  • Subcellular fractionation, combined with Western blotting, showed that PCSK9 is localized in the ER and intermediate vesicular compartment of the cell but not in Golgi cisternae.
  • The mature enzyme is secreted from the liver and hepatoma cells.
  • [MeSH-minor] Animals. Brefeldin A / pharmacology. COS Cells. Centrifugation, Density Gradient. Cercopithecus aethiops. Cholesterol / pharmacology. DNA, Complementary / genetics. Female. Fetus / enzymology. Fluorescent Antibody Technique. Humans. Isoquinolines / pharmacology. Liver / enzymology. Male. Pregnancy. Protein Transport / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Rats, Sprague-Dawley. Sulfonamides / pharmacology. Tumor Cells, Cultured. Yolk Sac / enzymology

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462892.001).
  • [ISSN] 0829-8211
  • [Journal-full-title] Biochemistry and cell biology = Biochimie et biologie cellulaire
  • [ISO-abbreviation] Biochem. Cell Biol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK59321
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Isoquinolines; 0 / RNA, Messenger; 0 / Sulfonamides; 127243-85-0 / N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; 20350-15-6 / Brefeldin A; 97C5T2UQ7J / Cholesterol; EC 3.4.21.- / PCSK9 protein, rat; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


15. Miura N, Nakamura H, Sato R, Tsukamoto T, Harada T, Takahashi S, Adachi Y, Shomori K, Sano A, Kishimoto Y, Ito H, Hasegawa J, Shiota G: Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci; 2006 Dec;97(12):1366-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a newly developed assay of telomerase reverse transcriptase (hTERT) mRNA in serum by real-time RT-PCR, we previously reported this assay to be superior to other tumor markers for hepatoma.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. RNA, Messenger / blood. Receptor, Epidermal Growth Factor / genetics. Telomerase / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / secondary. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Neoplastic Cells, Circulating. Prognosis. RNA, Neoplasm / blood. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17052260.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


21. Feng WW, Wang TN, Chen HC, Ho JC, Ko YC: Malignancies after renal transplantation in southern Taiwan: experience in one centre. BJU Int; 2007 Apr;99(4):825-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second most frequent type was hepatoma, where the CIR was 1.77%.
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. Taiwan / epidemiology


22. Wong LL, Limm W, Cheung A, Noguchi H: Liver transplant in Hawaii: the survival of a small centre. Clin Transplant; 2006 Jan-Feb;20(1):55-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplant in Hawaii: the survival of a small centre.
  • Although many report the importance of case volume in complex cases, liver transplantation (LT) can be carried out successfully in a small centre.
  • Indications for LT were primarily hepatitis C (n = 49) and hepatitis B (n = 13) and 22 patients (25%) had hepatocellular cancer (HCC) on explanted liver.
  • There was no primary graft nonfunction, one retransplant for recurrent hepatitis C and two late hepatic artery thromboses, which did not require a retransplant.
  • During this time period, 142 liver resections, 77 pancreatic resections and 43 splenorenal shunts were performed by this group of surgeons.
  • [MeSH-major] Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Female. Hawaii. Hepatitis B / surgery. Hepatitis C / surgery. Humans. Male. Middle Aged. Quality of Health Care. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556154.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


23. Nishimura T, Azuma T, Yokoyama A, Ochiai H, Saito H, Hibi T: New mechanism of transforming growth factor-beta signaling in hepatoma: Dramatic up-regulation of tumor initiating cells and epidermal growth factor receptor expression. Hepatol Res; 2009 May;39(5):501-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New mechanism of transforming growth factor-beta signaling in hepatoma: Dramatic up-regulation of tumor initiating cells and epidermal growth factor receptor expression.
  • We studied the effect of TGF-beta on tumor-initiating cells (TICs), which are similar in self-renewal and differentiation features to normal adult stem cells.
  • METHODS: We used side population (SP) cells that exclude DNA binding dye Hoechst 33342 to obtain TICs, studied the differences in the kinetics of the SP cell response to TGF-beta treatment between hepatic tumor cell lines, and performed gene analysis.
  • RESULTS: SP cells from all cell lines have higher proliferative ability compared to non-SP cells and they are drug resistant.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261001.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Liu YB, Jian ZX, Ou JR, Liu ZX: [Treatment and surgery of primary hepatic cancer with portal vengus tumor thrombosis]. Zhonghua Wai Ke Za Zhi; 2005 Apr 1;43(7):436-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and surgery of primary hepatic cancer with portal vengus tumor thrombosis].
  • OBJECTIVE: To study the methods of surgery for hepatocellular carcinoma (HCC) with tumor thrombi in portal vein (TTPV).
  • 101 patients had operation treatment, 23 of them underwent hepatoma resection, and average survival time was 10.9 months; 78 patients underwent hepatoma resection and removal of tumor thrombi, and average survival time was 26.8 months.
  • CONCLUSIONS: Operation treatment can comparatively extend the survival time of hepatocellular carcinoma with tumor thrombi in portal vein patients, and the best choice is hepatoma resection and removal of tumor thrombi, hepatic artery and portal vein chemoembolization after operation can enhance the effect.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery. Neoplastic Cells, Circulating. Portal Vein / pathology
  • [MeSH-minor] Adult. Aged. Chemoembolization, Therapeutic. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Portal thrombosis.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854368.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


25. Moffat ID, Boutros PC, Celius T, Lindén J, Pohjanvirta R, Okey AB: microRNAs in adult rodent liver are refractory to dioxin treatment. Toxicol Sci; 2007 Oct;99(2):470-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] microRNAs in adult rodent liver are refractory to dioxin treatment.
  • We used two miRNA array platforms as well as quantitative reverse transcriptase-polymerase chain reaction to measure miRNA levels in wild-type (WT) versus Ahr-null mice, in dioxin-sensitive Long-Evans (L-E; Turku/AB) rats versus dioxin-resistant Han/Wistar (H/W; Kuopio) rats and in rat 5L and mouse Hepa-1 hepatoma cells in culture.
  • Hepatoma cells in culture also exhibited few changes in miRNA levels in response to TCDD.
  • It is unlikely that mRNA downregulation by dioxins is mediated by miRNAs, nor are miRNAs likely to play a significant role in dioxin toxicity in adult rodent liver.
  • [MeSH-major] Liver / drug effects. MicroRNAs / analysis. Tetrachlorodibenzodioxin / toxicity

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698510.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Receptors, Aryl Hydrocarbon; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


26. Marikawa Y, Fujita TC, Alarcón VB: Heterogeneous DNA methylation status of the regulatory element of the mouse Oct4 gene in adult somatic cell population. Cloning Stem Cells; 2005;7(1):8-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneous DNA methylation status of the regulatory element of the mouse Oct4 gene in adult somatic cell population.
  • Bisulfite analysis showed that the regulatory element was unmethylated in P19 embryonal carcinoma cells, which robustly express Oct4.
  • By contrast, the regulatory element was distinctly methylated in somatic cells, including cell lines, such as NIH3T3 embryonic fibroblast and Hepa1-6 hepatoma, as well as tissues from the adult body, such as liver, spleen, and cumulus cells.
  • However, we found that the extent of methylation was considerably heterogeneous among the alleles in the adult somatic cells.
  • These results raise the possibility that the epigenetic status of Oct4 is heterogeneous among a population of somatic cells, which may affect the efficiency of Oct4 reactivation after somatic cell nuclear transfer.
  • [MeSH-minor] Alleles. Animals. Cell Line, Tumor. Cell Nucleus / metabolism. CpG Islands. Female. Fibroblasts / metabolism. Genes, Reporter. Humans. Luciferases / metabolism. Mice. Mice, Inbred C57BL. Mice, Inbred DBA. Models, Genetic. NIH 3T3 Cells. Octamer Transcription Factor-3. Plasmids / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sulfites / pharmacology. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996113.001).
  • [ISSN] 1536-2302
  • [Journal-full-title] Cloning and stem cells
  • [ISO-abbreviation] Cloning Stem Cells
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR 16467
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / Pou5f1 protein, mouse; 0 / Sulfites; 0 / Transcription Factors; EC 1.13.12.- / Luciferases
  •  go-up   go-down


27. Ng SK, Neo SY, Yap YW, Karuturi RK, Loh ES, Liau KH, Ren EC: Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation. Biochem Biophys Res Commun; 2009 Sep 18;387(2):310-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation.
  • Cancer such as hepatocellular carcinoma (HCC) is characterized by complex perturbations in multiple signaling pathways, including the phosphoinositide-3-kinase (PI3K/AKT) pathways.
  • Among the siRNAs tested against the eight known catalytic PI3K isoforms, specific ablation of class II PI3K alpha (PIK3C2alpha) was the most effective in impairing cell growth and this was accompanied by concomitant decrease in PIK3C2alpha mRNA and protein levels.
  • Taken together, these data suggest for the first time that in addition to class I PI3Ks in cancer, class II PIK3C2alpha can modulate HCC cell growth.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Cell Proliferation. Liver Neoplasms / pathology. Phosphatidylinositol 3-Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / genetics. Base Sequence. Caspase 3 / metabolism. Class II Phosphatidylinositol 3-Kinases. Female. Humans. Male. Middle Aged. Molecular Sequence Data. RNA, Small Interfering / genetics. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19591801.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / Class II Phosphatidylinositol 3-Kinases; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


28. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, Zhao QC, Tian R, Feng Q, Zhang SH, Li Y, Jiang JL, Li L, Yu XL, Zhang Z, Chen ZN: A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology; 2007 Feb;45(2):269-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation.
  • Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Liver Transplantation. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Antigens, CD147 / immunology. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Single-Blind Method. Survival Rate. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2007 Jul;13(7):1057-8 [17600354.001]
  • [CommentIn] Hepatology. 2007 Feb;45(2):263-5 [17256762.001]
  • (PMID = 17256759.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / BSG protein, human; 0 / alpha-Fetoproteins; 0 / metuximab; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


29. Nishimura FT, Kimura Y, Abe S, Fukunaga T, Saijoh K: Effect of -361 G/A polymorphism of aldehyde dehydrogenase-2 gene on alcohol metabolism and its expression in human peripheral blood leukocytes. Nihon Arukoru Yakubutsu Igakkai Zasshi; 2006 Apr;41(2):108-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to this locus, polymorphism in -361 G/A mutation of this gene at 5'flanking region, commonly found in multi-racial populations, is one of the suggestive polymorphisms which may affect on the enzyme activity because it has been reported to affect on the transcriptional activity in hepatoma cells.
  • [MeSH-minor] Adult. Asian Continental Ancestry Group. Humans. Japan. Male. RNA, Messenger / analysis

  • Hazardous Substances Data Bank. ETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734278.001).
  • [ISSN] 1341-8963
  • [Journal-full-title] Nihon Arukōru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence
  • [ISO-abbreviation] Nihon Arukoru Yakubutsu Igakkai Zasshi
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger; 3K9958V90M / Ethanol; EC 1.2.1.3 / ALDH2 protein, human; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


30. Srisawat N, Avihingsanon A, Praditpornsilpa K, Jiamjarasrangsi W, Eiam-Ong S, Avihingsanon Y: A prevalence of posttransplantation cancers compared with cancers in people with human immunodeficiency virus/acquired immunodeficiency syndrome after highly active antiretroviral therapy. Transplant Proc; 2008 Oct;40(8):2677-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risks of developing hepatoma and non-Hodgkin's lymphoma were comparable between the groups.
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / epidemiology. Female. Humans. Liver Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Male. Middle Aged. Prevalence. Retrospective Studies. Survival Analysis. Uterine Cervical Neoplasms / epidemiology


31. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N: Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol; 2005 Dec;43(6):1013-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.
  • BACKGROUND/AIMS: MHC class I-related chain A (MICA), a human ligand of natural killer (NK) cell stimulatory receptor NKG2D, is expressed in human hepatocellular carcinomas (HCC).
  • In vitro experiments were performed to examine the impact of sMICA on NK cell expression of NKG2D and subsequent dendritic cell (DC) activation.
  • In vitro experiments revealed that sMICA derived from advanced HCC was responsible for down-modulation of NKG2D expression and NK cell functions.
  • NK cells upon stimulation of human hepatoma cells induced maturation of DC and enhanced the allostimulatory capacity of DC; maturation and activation of DC were completely abolished when NK cells were pre-treated with sMICA-containing serum.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Dendritic Cells / immunology. Histocompatibility Antigens Class I / immunology. Killer Cells, Natural / immunology. Liver Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis, Chronic / immunology. Humans. Male. Middle Aged. NK Cell Lectin-Like Receptor Subfamily K. Receptors, Immunologic / immunology. Receptors, Natural Killer Cell

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168521.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / KLRK1 protein, human; 0 / MHC class I-related chain A; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Receptors, Immunologic; 0 / Receptors, Natural Killer Cell
  •  go-up   go-down


32. Chang KC, Tai MH, Lin JW, Wang CC, Huang CC, Hung CH, Chen CH, Lu SN, Lee CM, Changchien CS, Hu TH: Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer; 2007 Sep 1;121(5):1059-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors.
  • Hepatoma-derived growth factor (HDGF) is a novel growth factor and elevated in several types of cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17487837.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / hepatoma-derived growth factor
  •  go-up   go-down


33. Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton RG, Roundtree S, Thomas DL, McKeating J, Cox A: Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis; 2005 Sep 01;41(5):667-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For neutralization assays, plasma was incubated with human immunodeficiency virus (HIV)-HCV H77 or control HIV-murine leukemia virus (MLV) pseudotype virus and then allowed to infect Hep3B hepatoma cells.
  • [MeSH-minor] Acute Disease. Adult. Female. Humans. Immunoglobulin G / blood. Male. RNA, Viral / blood. Time Factors. Viral Proteins / immunology. Viremia

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080089.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK068555; United States / NIAID NIH HHS / AI / U19 AI040035; United States / NIAID NIH HHS / AI / U19 AI40035; United Kingdom / Medical Research Council / / G0400802; United States / NIDA NIH HHS / DA / K08 DA016535-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis C Antibodies; 0 / Immunoglobulin G; 0 / RNA, Viral; 0 / Viral Proteins
  •  go-up   go-down


34. Salguero FJ, Richard A, Gough J, Long A, Weyer U, Cooley WA, Chambers MA, Lesellier S: Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles). J Comp Pathol; 2010 Feb-Apr;142(2-3):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles).
  • A mass was identified within the left lateral lobe of the liver of a 10-year-old Eurasian badger (Meles meles).
  • The histological appearance was consistent with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / veterinary. Liver / pathology. Liver Neoplasms / veterinary. Mustelidae

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19683720.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ: Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol; 2007 Jul 1;222(1):42-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues.
  • Frequently, primary hepatocytes are used as an in vitro model for the liver in vivo.
  • In this study, we characterized the differentiation character of primary human hepatocytes cultured using a highly defined, serum-free two-dimensional sandwich system, one that configures hepatocytes with collagen I as the substratum together with a dilute extracellular matrix (Matrigeltrade mark) overlay combined with a defined serum-free medium containing nanomolar levels of dexamethasone.
  • Whole genome expression profiling enabled direct comparison of liver tissues to hepatocytes and to the hepatoma-derived cell lines, HepG2 and Huh7.
  • The robustness of the primary hepatocyte cultures was reflected by the extent of unchanged expression character when compared directly to liver, with more than 77% of the probe sets unchanged in each of the over-represented categories, representing such genes as C/EBPalpha, HNF4alpha, CYP2D6, and ABCB1.
  • In contrast, HepG2 and Huh7 cells were unchanged from the liver tissues for fewer than 48% and 55% of these probe sets, respectively.
  • Further, hierarchical clustering of the hepatocytes, but not the cell lines, shifted from donor-specific to treatment-specific when the probe sets were filtered to focus on phenobarbital-inducible genes, indicative of the highly differentiated nature of the hepatocytes when cultured in a highly defined two-dimensional sandwich system.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Phenobarbital .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W645-50 [16912992.001]
  • [Cites] Toxicol In Vitro. 2002 Feb;16(1):89-99 [11812644.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • [Cites] Biochem Pharmacol. 2001 May 15;61(10):1293-303 [11322933.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Toxicol Sci. 2002 Jun;67(2):219-31 [12011481.001]
  • [Cites] Xenobiotica. 2002 Jun;32(6):505-20 [12160483.001]
  • [Cites] Science. 2002 Oct 11;298(5592):422-4 [12376703.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):386-402 [12657743.001]
  • [Cites] Mol Endocrinol. 2003 Jul;17(7):1268-82 [12663745.001]
  • [Cites] Drug Metab Dispos. 2003 Aug;31(8):1035-42 [12867492.001]
  • [Cites] Toxicol Sci. 2003 Sep;75(1):208-22 [12832660.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2129-41 [12952881.001]
  • [Cites] Exp Cell Res. 2004 Jan 15;292(2):252-64 [14697333.001]
  • [Cites] Mol Pharmacol. 2004 Mar;65(3):550-7 [14978233.001]
  • [Cites] Genomics. 2004 Apr;83(4):541-9 [15028276.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22250-7 [15004017.001]
  • [Cites] Pharm Res. 2004 Jul;21(7):1294-302 [15290872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2161-5 [3353374.001]
  • [Cites] Arch Biochem Biophys. 1993 Feb 15;301(1):103-13 [8442654.001]
  • [Cites] Biomaterials. 1996 Feb;17(3):373-85 [8745335.001]
  • [Cites] Methods Enzymol. 1996;272:388-401 [8791798.001]
  • [Cites] Toxicol Pathol. 1996 Jan-Feb;24(1):48-57 [8839280.001]
  • [Cites] Arch Biochem Biophys. 1997 Jan 15;337(2):275-83 [9016823.001]
  • [Cites] Biochem Pharmacol. 1997 Oct 1;54(7):761-72 [9353130.001]
  • [Cites] Drug Metab Dispos. 1999 Jun;27(6):637-44 [10348791.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):887-94 [10421615.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):909-15 [10421618.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49517-22 [15358766.001]
  • [Cites] Drug Metab Dispos. 2005 Mar;33(3):388-94 [15608134.001]
  • [Cites] Toxicol Sci. 2005 Jun;85(2):927-34 [15772367.001]
  • [Cites] BMC Genomics. 2005;6:59 [15854232.001]
  • [Cites] Reprod Toxicol. 2005 Sep-Oct;20(3):433-40 [15964738.001]
  • [Cites] Toxicology. 2006 Feb 1;218(2-3):205-15 [16337326.001]
  • [Cites] BMC Bioinformatics. 2006;7:49 [16448562.001]
  • [Cites] Mol Pharmacol. 2002 Jan;61(1):1-6 [11752199.001]
  • [Cites] BMC Bioinformatics. 2006;7:359 [16872483.001]
  • (PMID = 17512962.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES011387-02; United States / NIEHS NIH HHS / ES / U19 ES011387-05; United States / NIGMS NIH HHS / GM / R01 GM066411-03; United States / NIGMS NIH HHS / GM / R01 GM066411; United States / NIEHS NIH HHS / ES / ES011387-04; United States / NIGMS NIH HHS / GM / GM066411-01; United States / NIEHS NIH HHS / ES / U19 ES011387-05S1; United States / NIGMS NIH HHS / GM / GM066411; United States / NIEHS NIH HHS / ES / P30 ES005022; United States / NIEHS NIH HHS / ES / ES011387-01; United States / NIEHS NIH HHS / ES / U19 ES011387; United States / NIGMS NIH HHS / GM / R01 GM066411-01; United States / NIGMS NIH HHS / GM / GM066411-04; United States / NIEHS NIH HHS / ES / U19 ES011387-04; United States / NIEHS NIH HHS / ES / ES011387-03; United States / NIGMS NIH HHS / GM / R01 GM066411-02; United States / NIEHS NIH HHS / ES / U19 ES11387; United States / NIGMS NIH HHS / GM / GM066411-02; United States / NIEHS NIH HHS / ES / ES011387-05S1; United States / NIEHS NIH HHS / ES / U19 ES011387-01; United States / NIEHS NIH HHS / ES / U19 ES011387-03; United States / NIEHS NIH HHS / ES / ES011387-05; United States / NIGMS NIH HHS / GM / GM066411-03; United States / NIEHS NIH HHS / ES / U19 ES011387-02; United States / NIGMS NIH HHS / GM / R01 GM066411-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Biomarkers; 63231-63-0 / RNA; YQE403BP4D / Phenobarbital
  • [Other-IDs] NLM/ NIHMS243113; NLM/ PMC2974173
  •  go-up   go-down


36. Chin KT, Zhou HJ, Wong CM, Lee JM, Chan CP, Qiang BQ, Yuan JG, Ng IO, Jin DY: The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. Nucleic Acids Res; 2005;33(6):1859-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma.
  • In search of proteins closely related to LZIP, we have identified a liver-enriched transcription factor CREB-H.
  • CREB-H transcript is exclusively abundant in adult liver.
  • In contrast, the expression of CREB-H mRNA is aberrantly reduced in hepatoma tissues and cells.
  • The enforced expression of CREB-H suppresses the proliferation of cultured hepatoma cells.
  • Taken together, our findings suggest that the liver-enriched bZIP transcription factor CREB-H is a growth suppressor that plays a role in hepatic physiology and pathology.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver / metabolism. Liver Neoplasms / metabolism. Transcription Factors / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Activating Transcription Factor 6. Animals. Cell Line, Tumor. Cyclic AMP / metabolism. Cyclic AMP Response Element-Binding Protein. DNA-Binding Proteins / metabolism. Humans. Mice. Molecular Sequence Data. Phosphoenolpyruvate Carboxykinase (ATP) / genetics. Response Elements. Transcriptional Activation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Institute for Transcriptional Informatics. gene/protein/disease-specific - Institute for Transcriptional Informatics (registration required).
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 2002 May 1;275(2):143-54 [11969286.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):20020-5 [11916968.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 26;293(1):470-7 [12054625.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(16):5639-49 [12138176.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(18):6321-35 [12192032.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):43895-902 [12237288.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1389-98 [12438434.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Dec;108(1-2):129-38 [12480185.001]
  • [Cites] J Biol Chem. 2003 Mar 21;278(12):10824-30 [12531887.001]
  • [Cites] Hepatology. 2003 Apr;37(4):731-8 [12668962.001]
  • [Cites] EMBO J. 2003 May 15;22(10):2360-9 [12743030.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1249-53 [12774000.001]
  • [Cites] Science. 2003 Jun 27;300(5628):2097-101 [12805554.001]
  • [Cites] Hum Mol Genet. 2003 Sep 15;12(18):2349-58 [12915480.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37439-50 [12876282.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7448-59 [14559994.001]
  • [Cites] Hepatology. 2003 Dec;38(6):1331-47 [14647040.001]
  • [Cites] Cell. 2004 Oct 1;119(1):61-74 [15454081.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Sep;79(17):5137-41 [6291025.001]
  • [Cites] J Biol Chem. 1984 Oct 10;259(19):12161-9 [6090458.001]
  • [Cites] Cell. 1988 May 6;53(3):451-61 [3365768.001]
  • [Cites] J Biol Chem. 1989 Jun 5;264(16):9657-64 [2542317.001]
  • [Cites] Genes Dev. 1991 Sep;5(9):1553-67 [1884998.001]
  • [Cites] Genes Dev. 1992 Mar;6(3):466-80 [1532159.001]
  • [Cites] Mol Cell Biol. 1992 Sep;12(9):4123-31 [1508208.001]
  • [Cites] J Biol Chem. 1995 Apr 7;270(14):8225-32 [7713929.001]
  • [Cites] Science. 1995 Aug 25;269(5227):1108-12 [7652557.001]
  • [Cites] Genes Dev. 1996 Apr 1;10(7):804-15 [8846917.001]
  • [Cites] Nucleic Acids Res. 1997 Jan 15;25(2):379-87 [9016568.001]
  • [Cites] Genes Dev. 1997 Mar 15;11(6):726-37 [9087427.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):4957-66 [9271374.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5117-26 [9271389.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7353-61 [9372966.001]
  • [Cites] Genes Dev. 1997 Dec 1;11(23):3122-7 [9389645.001]
  • [Cites] Mol Cell. 1997 Dec;1(1):47-57 [9659902.001]
  • [Cites] Mol Cell. 1998 Oct;2(4):505-14 [9809072.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):31629-32 [9822619.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33741-9 [9837962.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2936-45 [10082561.001]
  • [Cites] Brain Res Mol Brain Res. 1999 May 21;69(1):93-103 [10350641.001]
  • [Cites] Mol Pathol. 1999 Feb;52(1):19-24 [10439834.001]
  • [Cites] Nucleic Acids Res. 1999 Sep 1;27(17):3621-30 [10446255.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):186-94 [15665855.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):721-33 [11830526.001]
  • [Cites] Mol Biol Cell. 1999 Nov;10(11):3787-99 [10564271.001]
  • [Cites] J Virol. 2000 Jan;74(2):934-43 [10623756.001]
  • [Cites] Mol Cell. 1999 Dec;4(6):1087-92 [10635333.001]
  • [Cites] EMBO J. 2000 Feb 15;19(4):729-40 [10675342.001]
  • [Cites] Mech Dev. 2000 Mar 15;92(1):83-8 [10704889.001]
  • [Cites] Cell. 2000 May 26;101(5):451-4 [10850487.001]
  • [Cites] Mol Cell Endocrinol. 2000 Apr 25;162(1-2):1-7 [10854692.001]
  • [Cites] Annu Rev Biochem. 1999;68:821-61 [10872467.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6755-67 [10958673.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):27013-20 [10856300.001]
  • [Cites] Dev Dyn. 2000 Oct;219(2):131-42 [11002334.001]
  • [Cites] Biochem J. 2000 Dec 1;352 Pt 2:335-42 [11085926.001]
  • [Cites] Mol Cell. 2000 Dec;6(6):1355-64 [11163209.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):9199-205 [11112790.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3176-81 [11306505.001]
  • [Cites] Nucleic Acids Res. 2001 May 15;29(10):2154-62 [11353085.001]
  • [Cites] Annu Rev Nutr. 2001;21:141-65 [11375433.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29200-9 [11369759.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28933-8 [11384994.001]
  • [Cites] Gene. 2001 Jul 25;273(1):1-11 [11483355.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):179-83 [11557984.001]
  • [Cites] Histochem Cell Biol. 2001 Aug;116(2):141-8 [11685542.001]
  • [Cites] Mol Cell. 2001 Oct;8(4):817-28 [11684017.001]
  • [Cites] Cell. 2001 Dec 28;107(7):881-91 [11779464.001]
  • [Cites] Genes Dev. 2002 Feb 15;16(4):452-66 [11850408.001]
  • [Cites] EMBO J. 2002 Mar 1;21(5):930-41 [11867521.001]
  • [Cites] Pharmacol Rev. 2002 Mar;54(1):129-58 [11870262.001]
  • [Cites] Endocrinology. 2002 May;143(5):1578-88 [11956138.001]
  • (PMID = 15800215.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF392874
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ATF6 protein, human; 0 / Activating Transcription Factor 6; 0 / Atf6 protein, mouse; 0 / Creb3l3 protein, mouse; 0 / Cyclic AMP Response Element-Binding Protein; 0 / DNA-Binding Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; E0399OZS9N / Cyclic AMP; EC 4.1.1.49 / Phosphoenolpyruvate Carboxykinase (ATP)
  • [Other-IDs] NLM/ PMC1072803
  •  go-up   go-down


37. Pichard-Garcia L, Briolotti P, Larrey D, Sa-Cunha A, Suc B, Laporte S, Maurel P: Use of human hepatocytes to investigate HCV infection. Methods Mol Biol; 2010;640:447-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different systems have been constructed based on hepatoma or other cell lines, sub-genomic and genomic replicons, productive replicons, and immortalized hepatocytes.
  • Adult primary human hepatocytes infected with natural serum-derived HCV virions represent the model that most closely mimics the physiological situation.

  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645067.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9008-11-1 / Interferons
  •  go-up   go-down


38. Park KH, Yun CO, Kwon OJ, Kim CH, Kim JR, Cho KH: Enhanced delivery of adenovirus, using proteoliposomes containing wildtype or V156K apolipoprotein A-I and dimyristoylphosphatidylcholine. Hum Gene Ther; 2010 May;21(5):579-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, treatment of Ad in the PL state showed enhanced green fluorescent protein (GFP) expression when compared with treatment with Ad alone or with DMPC-Ad in hepatoma and brain glioma cells.
  • Furthermore, V156K-PL-Ad showed the highest expression of GFP in adult zebrafish (9 weeks old) at 5 days postinjection (10.5- and 3.8-fold more GFP expressed than by Ad only and DMPC-Ad, respectively).

  • Hazardous Substances Data Bank. GUANIDINE .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038214.001).
  • [ISSN] 1557-7422
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Liposomes; 0 / Proteolipids; 0 / proteoliposomes; 147336-22-9 / Green Fluorescent Proteins; 97C5T2UQ7J / Cholesterol; JU58VJ6Y3B / Guanidine; U86ZGC74V5 / Dimyristoylphosphatidylcholine
  •  go-up   go-down


39. Lanka B, Jang HJ, Kim TK, Burns PN, Wilson SR: Impact of contrast-enhanced ultrasonography in a tertiary clinical practice. J Ultrasound Med; 2007 Dec;26(12):1703-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was to assess the impact of contrast-enhanced ultrasonography (CEUS) of the liver in a tertiary clinical practice.
  • RESULTS: Two hundred seventy-five (26.4%) of 1040 examinations were motivated by incidental detection of a mass at routine ultrasonography; 765 (73.6%) were clinical referrals, most often for characterization of a mass in a high-risk patient scanned for hepatoma surveillance or characterization of an indeterminate mass after prior imaging.
  • Surveillance scans yielded 78 confirmed hepatocellular carcinomas characterized on CEUS at the time of identification.
  • Negative impacts included delayed management in 8 (0.8%) small hepatocellular carcinomas misdiagnosed as benign lesions and wrong management of a solitary sclerotic hemangioma, in a high-risk patient for hepatoma, misdiagnosed as a malignant tumor on CEUS, computed tomography, and magnetic resonance imaging, leading to its surgical removal.
  • [MeSH-major] Critical Pathways / statistics & numerical data. Fluorocarbons. Liver Neoplasms / epidemiology. Liver Neoplasms / ultrasonography. Practice Patterns, Physicians' / statistics & numerical data. Ultrasonography / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Contrast Media. Female. Humans. Male. Middle Aged. Ontario / epidemiology. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Ultrasound Med. 2008 Jun;27(6):991-2 [18499863.001]
  • (PMID = 18029922.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Definity; 0 / Fluorocarbons
  •  go-up   go-down


40. Long M, Deutch B, Bonefeld-Jorgensen EC: AhR transcriptional activity in serum of Inuits across Greenlandic districts. Environ Health; 2007;6:32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effects of the serum extract on the AhR transactivity was determined using the Hepa 1.12cR mouse hepatoma cell line carrying an AhR-luciferase reporter gene, and the data was evaluated for possible association to the serum levels of 14 PCB congeners, 10 organochlorine pesticide residues and/or lifestyle factors.
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Benzofurans / blood. Benzofurans / pharmacology. Cell Line, Tumor. Environmental Monitoring / methods. Female. Food Chain. Food Habits. Greenland. Humans. Male. Mice. Middle Aged. Polychlorinated Biphenyls / blood. Polychlorinated Biphenyls / pharmacology. Tetrachlorodibenzodioxin / analogs & derivatives. Tetrachlorodibenzodioxin / blood. Tetrachlorodibenzodioxin / pharmacology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Toxicol Suppl. 1995;17:99-115 [7786196.001]
  • [Cites] Environ Health Perspect. 1995 Mar;103 Suppl 2:135-42 [7614935.001]
  • [Cites] Eur J Pharmacol. 1995 May 26;293(1):1-40 [7545581.001]
  • [Cites] Fundam Appl Toxicol. 1996 Apr;30(2):194-203 [8812265.001]
  • [Cites] Mol Cell Endocrinol. 2005 Dec 1;244(1-2):20-30 [16219411.001]
  • [Cites] Chemosphere. 2005 Dec;61(11):1672-6 [15939454.001]
  • [Cites] Environ Health. 2005;4:27 [16283941.001]
  • [Cites] Environ Health. 2006;5:14 [16725033.001]
  • [Cites] Toxicol Sci. 2006 Oct;93(2):223-41 [16829543.001]
  • [Cites] Sci Total Environ. 2006 Nov 1;370(2-3):372-81 [16904734.001]
  • [Cites] Sci Total Environ. 2007 Jan 1;372(2-3):486-96 [17157358.001]
  • [Cites] Environ Health Perspect. 2007 Dec;115 Suppl 1:69-76 [18174953.001]
  • [Cites] Environ Health Perspect. 1996 May;104(5):550-7 [8743444.001]
  • [Cites] Eur J Pharmacol. 1995 Dec 7;293(4):463-74 [8748700.001]
  • [Cites] Fundam Appl Toxicol. 1996 Sep;33(1):149-60 [8812260.001]
  • [Cites] Crit Rev Toxicol. 1997 Mar;27(2):109-34 [9099515.001]
  • [Cites] Chemosphere. 1997 Mar-Apr;34(5-7):1459-68 [9134679.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1651-4 [9276643.001]
  • [Cites] Arch Environ Contam Toxicol. 1997 Oct;33(3):298-311 [9353208.001]
  • [Cites] Environ Health Perspect. 1998 Dec;106(12):775-92 [9831538.001]
  • [Cites] Environ Health Perspect. 1999 Oct;107(10):823-8 [10504150.001]
  • [Cites] Environ Health. 2003 Oct 15;2(1):12 [14613489.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2005 Jul;15(4):310-8 [15383834.001]
  • [Cites] Environ Health Perspect. 2005 Oct;113(10):1318-24 [16203240.001]
  • [Cites] Environ Sci Technol. 2005 Oct 1;39(19):7357-64 [16245802.001]
  • [Cites] Toxicol Sci. 2000 Mar;54(1):183-93 [10746945.001]
  • [Cites] Dan Med Bull. 2000 Apr;47(2):132-7 [10822803.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108(6):553-7 [10856030.001]
  • [Cites] Food Addit Contam. 2000 Apr;17(4):347-58 [10912248.001]
  • [Cites] Toxicology. 2001 Feb 14;158(3):141-53 [11275356.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3942-8 [11358810.001]
  • [Cites] Chemosphere. 2001 May-Jun;43(4-7):807-14 [11372869.001]
  • [Cites] Environ Int. 2001 Nov;27(5):413-39 [11757855.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):629-35 [11914190.001]
  • [Cites] Environ Health Perspect. 2002 Jul;110(7):617-24 [12117636.001]
  • [Cites] Food Chem Toxicol. 2002 Nov;40(11):1685-92 [12176094.001]
  • [Cites] Chemosphere. 2002 Sep;48(8):827-32 [12222776.001]
  • [Cites] Sci Total Environ. 2003 Jan 20;302(1-3):27-52 [12526896.001]
  • [Cites] Chemosphere. 2003 Mar;50(9):1193-200 [12547333.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Feb 15;187(1):11-21 [12628580.001]
  • [Cites] Arch Environ Health. 2003 Jan;58(1):30-6 [12747516.001]
  • [Cites] Food Addit Contam. 2003 Jun;20(6):583-95 [12881133.001]
  • [Cites] Toxicology. 2003 Dec 15;194(1-2):77-93 [14636698.001]
  • [Cites] Toxicol Lett. 2004 Jun 15;151(1):51-61 [15177640.001]
  • [Cites] Sci Total Environ. 2004 Sep 1;330(1-3):55-70 [15325158.001]
  • [Cites] Sci Total Environ. 2004 Sep 20;331(1-3):29-52 [15325140.001]
  • [Cites] Sci Total Environ. 2004 Sep 20;331(1-3):157-75 [15325147.001]
  • [Cites] Sci Total Environ. 2004 Sep 20;331(1-3):177-88 [15325148.001]
  • [Cites] Sci Total Environ. 2004 Sep 20;331(1-3):189-206 [15325149.001]
  • [Cites] Sci Total Environ. 2004 Sep 20;331(1-3):215-31 [15325151.001]
  • [Cites] Environ Health Perspect. 2004 Sep;112(13):1265-8 [15345337.001]
  • [Cites] Environ Toxicol. 2004 Oct;19(5):480-9 [15352264.001]
  • [Cites] Toxicol Appl Pharmacol. 1969 Mar;14(2):358-67 [5772860.001]
  • [Cites] Toxicology. 1987 Oct 12;46(1):29-42 [3116725.001]
  • [Cites] Sci Total Environ. 1992 Jul 15;122(1-2):1-74 [1514103.001]
  • [Cites] Sci Total Environ. 1992 Jul 15;122(1-2):247-78 [1514105.001]
  • [Cites] Am J Clin Nutr. 1993 May;57(5):629-33 [8480677.001]
  • [Cites] Toxicol Appl Pharmacol. 1994 Jun;126(2):326-37 [8209386.001]
  • [Cites] Crit Rev Toxicol. 1994;24(2):87-149 [8037844.001]
  • (PMID = 17956617.001).
  • [ISSN] 1476-069X
  • [Journal-full-title] Environmental health : a global access science source
  • [ISO-abbreviation] Environ Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzofurans; 0 / Dioxins; 0 / Environmental Pollutants; 0 / Receptors, Aryl Hydrocarbon; 0 / chlorinated dibenzofurans; 0 / polychlorodibenzo-4-dioxin; DFC2HB4I0K / Polychlorinated Biphenyls; DO80M48B6O / Tetrachlorodibenzodioxin
  • [Other-IDs] NLM/ PMC2173889
  •  go-up   go-down


41. Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, Simon MT, Renard CA, Buendia MA, Perret C: Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene; 2006 Jan 26;25(4):599-608
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations.
  • The Wnt/beta-catenin signaling pathway is activated in many human hepatocellular carcinomas (HCC).
  • They encode the Regenerating islet-derived 3 alpha (REG3A/HIP/PAP/REG-III) and 1 alpha (REG1A) proteins, both involved in liver and pancreatic regeneration and proliferation.
  • Using siRNA directed against beta-catenin, we demonstrated that REG3A is a target of beta-catenin signaling in Huh7 hepatoma cells.
  • Thus, we report strong evidence that both genes are downstream targets of the Wnt pathway during liver tumorigenesis.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Lectins, C-Type / genetics. Lithostathine / genetics. Liver Neoplasms / genetics. Mutation. beta Catenin / genetics
  • [MeSH-minor] Adenoma / genetics. Adult. Cell Line, Tumor. Colonic Neoplasms / genetics. Hepatoblastoma / genetics. Humans. Male. Signal Transduction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314847.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / REG1A protein, human; 0 / beta Catenin; 0 / pancreatitis-associated protein
  •  go-up   go-down


42. Zhang FJ, Li CX, Wu PH, Li K, Huang JH, Fan WJ, Zhang L, Gu YK, Lu MJ, Wu YX, Wang JJ: [Radioactive seed 125I implantation in treating recurrence and metastasis after liver transplantation in hepatoma]. Zhonghua Yi Xue Za Zhi; 2007 Apr 10;87(14):956-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radioactive seed 125I implantation in treating recurrence and metastasis after liver transplantation in hepatoma].
  • OBJECTIVE: To investigate the clinical value of CT-guided radioactive seed (125)I implantation in treating recurrence and metastasis after liver transplantation in hepatoma.
  • METHODS: Eleven patients with recurrence and metastasis after liver transplantation for hepatoma, with 45 metastatic lesions, 2.5 cm in diameter on average totally 9 males and 2 females, aged 56 (35 approximately 68), underwent CT-guided radioactive seed 125I implantation for 33 man-times.
  • CONCLUSION: CT guided radioactive seed 125I implantation procedure has good clinical effects with minimal damage and few complications in treating recurrence and metastasis after liver transplantation in hepatoma.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Iodine Radioisotopes / therapeutic use. Liver Neoplasms / radiotherapy. Neoplasm Metastasis / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Brachytherapy / adverse effects. Brachytherapy / methods. Female. Follow-Up Studies. Hemorrhage / etiology. Humans. Liver Transplantation. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17650418.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


43. Saheki T, Kobayashi K, Iijima M, Moriyama M, Yazaki M, Takei Y, Ikeda S: Metabolic derangements in deficiency of citrin, a liver-type mitochondrial aspartate-glutamate carrier. Hepatol Res; 2005 Oct;33(2):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic derangements in deficiency of citrin, a liver-type mitochondrial aspartate-glutamate carrier.
  • Citrin, encoded by SLC25A13, is a liver-type mitochondrial aspartate-glutamate carrier (AGC), of which deficiency, in autosomal recessive trait, causes neonatal intrahepatic cholestasis (NICCD) and adult-onset type II citrullinemia (CTLN2).
  • NICCD patients have jaundice, hypoproteinemia, hypoglycemia, galactosemia, growth retardation, fatty liver and multiple aminoacidemia including citrulline, methionine, threonine and tyrosine.
  • Laboratory findings reveal hyperammonemia, citrullinemia, fatty liver and liver-specific decrease in a urea cycle enzyme, argininosuccinate synthetase (ASS).
  • In some cases, hyperlipidemia, pancreatitis and hepatoma are accompanied with CTLN2.
  • Citrin as a liver-type AGC plays a role in supplying aspartate to the cytosol for urea, protein and nucleotide synthesis by exchanging mitochondrial aspartate for cytosolic glutamate and proton, and transporting cytosolic NADH reducing equivalent to mitochondria as a member of malate aspartate shuttle essential for aerobic glycolysis.
  • Although it is difficult to explain pathogenesis of the symptoms such as cholestasis in NICCD and liver-specific decrease of ASS protein in CTLN2 from the functions of the AGC, some are understandable by the loss of citrin functions.
  • We argue that those treatments may result in fatty liver, hyperlipidemia, hyperammonemia and even death due to loss of the citrin functions.

  • Genetics Home Reference. consumer health - SLC25A13 gene.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16199199.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


44. Enomoto H, Nakamura H, Komatsu-Kanatani N, Liu Y, Yoshida K, Okuda Y, Yamamoto T, Liu W, Nishiguchi S: Partial blockage of hepatocyte maturation in hepatoma-derived growth factor transgenic mice. World J Hepatol; 2009 Oct 31;1(1):98-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial blockage of hepatocyte maturation in hepatoma-derived growth factor transgenic mice.
  • AIM: To investigate the role of hepatoma-derived growth factor (HDGF) in liver development, especially in the hepatocyte differentiation.
  • RESULTS: The HDGF transgenic mice developed normally and showed no apparent abnormality in the liver.
  • However, the gene expression patterns of the liver in adult transgenic mice were similar to those of the neonatal liver in control mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160971.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999260
  • [Keywords] NOTNLM ; Hepatocyte / Hepatoma-derived growth factor / Maturation / Transgenic mice
  •  go-up   go-down


45. Jariwalla RJ, Gangapurkar B, Nakamura D: Differential sensitivity of various human tumour-derived cell types to apoptosis by organic derivatives of selenium. Br J Nutr; 2009 Jan;101(2):182-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential sensitivity of various human tumour-derived cell types to apoptosis by organic derivatives of selenium.
  • In the present study, the apoptosis-inducing effects of organic selenium derivatives, namely methyl-L-selenocysteine and selenomethionine, were evaluated in vitro on human tumour-derived cell lines from breast, liver, colon, brain, skin and a non-tumorigenic line of epithelial origin.
  • Apoptosis was assessed by cell-death detection immunoassay on cytoplasmic cell lysates.
  • Breast carcinoma cells were highly sensitive to the organic selenium compounds, manifesting apoptosis at concentrations as low as 0.113 microm (0.0205 microg/ml) selenium.
  • The cell lines derived from hepatoma and neuroblastoma showed intermediate sensitivity, with colon carcinoma cells manifesting the lowest sensitivity to the trace element.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adolescent. Adult. Animals. Anticarcinogenic Agents / therapeutic use. Apoptosis / drug effects. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Survival. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Cysteine / analogs & derivatives. Cysteine / therapeutic use. Epithelial Cells / drug effects. Epithelial Cells / pathology. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Male. Melanoma / drug therapy. Melanoma / pathology. Middle Aged. Neuroectodermal Tumors, Primitive, Peripheral / drug therapy. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Organoselenium Compounds / therapeutic use. Selenocysteine / analogs & derivatives. Selenomethionine / therapeutic use. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. SELENIUM COMPOUNDS .
  • Hazardous Substances Data Bank. SELENIUM METHIONINE .
  • Hazardous Substances Data Bank. SELENO-(DL)-CYSTEINE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18549510.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Organoselenium Compounds; 0 / Selenium Compounds; 0CH9049VIS / Selenocysteine; 964MRK2PEL / Selenomethionine; K848JZ4886 / Cysteine; TWK220499Z / selenomethylselenocysteine
  •  go-up   go-down


46. Serdyuk AP, Ozerova IN, Kamyshova TV, Perova NV, Metel'skaya VA: Impaired antiatherogenic function of high-density lipoproteins in the presence of various risk factors for coronary heart disease. Bull Exp Biol Med; 2005 Mar;139(3):290-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied acception of cholesterol from Fu5AH hepatoma cells by blood serum from subjects with normal level of high-density lipoprotein cholesterol and hyperlipidemia (alone or in combination with other risk factors for coronary heart disease).
  • [MeSH-minor] Adult. Blood Pressure. Body Mass Index. Body Weight. Carcinoma, Hepatocellular / metabolism. Cholesterol / blood. Cholesterol / metabolism. Humans. Hyperlipidemias / complications. Liver Neoplasms / metabolism. Male. Middle Aged. Risk Factors. Tumor Cells, Cultured. Urban Population

  • Genetic Alliance. consumer health - Heart Disease.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027833.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng; rus
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholesterol, HDL; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


47. Katayama K, Hashimoto N, Tanaka Y, Ozawa T, Emi Y, Ikeda T, Katayama M, Nomura S, Kitajima I, Nakano T, Imanaka T: Identification of a novel amino acid deletion mutation and a very rare single nucleotide variant in a Japanese family with type I antithrombin deficiency. Thromb Res; 2005;116(3):215-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To elucidate the mechanism of AT deficiency, we transiently expressed wild type and the mutant AT (DeltaM103) in HuH-7 human hepatoma cells and performed pulse-chase studies.
  • [MeSH-minor] Adult. Antithrombin III / genetics. Antithrombin III / secretion. Biological Transport. Blood Coagulation Disorders, Inherited / genetics. Cell Line, Tumor. Cloning, Molecular. DNA Mutational Analysis. Family Health. Gene Expression Regulation / genetics. Humans. Japan. Male. Pedigree. Transfection

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15935830.001).
  • [ISSN] 0049-3848
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9000-94-6 / Antithrombin III
  •  go-up   go-down


48. Kang KW, Kim YG: Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone-metabolizing enzyme AKR1C (aldo-keto reductase) family caused by estradiol. J Clin Pharmacol; 2008 Dec;48(12):1430-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors therefore measured the effects of estradiol on the expression of the tibolone-metabolizing enzymes, from the aldo-keto reductase (AKR1C) family, using HepG2 cell (human hepatoma cells) and MCF-7 cell (human breast cancer cells).
  • [MeSH-minor] 20-Hydroxysteroid Dehydrogenases / genetics. 20-Hydroxysteroid Dehydrogenases / metabolism. 3-Hydroxysteroid Dehydrogenases / genetics. 3-Hydroxysteroid Dehydrogenases / metabolism. Adult. Aldehyde Reductase. Area Under Curve. Cell Line, Tumor. Cross-Over Studies. Enzyme Activation / drug effects. Estrogen Receptor Modulators / metabolism. Estrogen Receptor Modulators / pharmacokinetics. Estrogen Receptor Modulators / pharmacology. Female. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Enzymologic / genetics. Glucose Transporter Type 1 / genetics. Glucose Transporter Type 1 / metabolism. Half-Life. Humans. Hydroxyprostaglandin Dehydrogenases / genetics. Hydroxyprostaglandin Dehydrogenases / metabolism. Hydroxysteroid Dehydrogenases / genetics. Hydroxysteroid Dehydrogenases / metabolism. Immunoblotting. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Therapeutic Equivalency. Young Adult

  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18832293.001).
  • [ISSN] 0091-2700
  • [Journal-full-title] Journal of clinical pharmacology
  • [ISO-abbreviation] J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3-hydroxytibolone; 0 / Estrogen Receptor Modulators; 0 / Glucose Transporter Type 1; 0 / Norpregnenes; 0 / RNA, Messenger; 0 / SLC2A1 protein, human; 4TI98Z838E / Estradiol; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; EC 1.1.- / Alcohol Oxidoreductases; EC 1.1.- / Hydroxysteroid Dehydrogenases; EC 1.1.1.- / 20-Hydroxysteroid Dehydrogenases; EC 1.1.1.- / 3 alpha-beta, 20 beta-hydroxysteroid dehydrogenase; EC 1.1.1.- / AKR1C2 protein, human; EC 1.1.1.- / AKR1C3 protein, human; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases; EC 1.1.1.184 / carbonyl reductase (NADPH); EC 1.1.1.21 / Aldehyde Reductase; FF9X0205V2 / tibolone
  •  go-up   go-down


49. Zhao W, Liu H, Liu W, Wu Y, Chen W, Jiang B, Zhou Y, Xue R, Luo C, Wang L, Jiang JD, Liu J: Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int J Oncol; 2006 May;28(5):1081-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration.
  • Liver cancer is the fifth most common neoplastic disease and the fourth leading cause of cancer-related death.
  • In this study, by conducting immunohistochemistry, we show that the neuronal protein, synuclein-gamma (SNCG), is abnormally expressed in a high percentage of liver cancer (46/70, 65.7%).
  • The expression of SNCG in liver cancer exhibits a clear stage-specific pattern of low expression in stage I (1/19, 5.3%) and high expression in stages III to IV (44/50, 88%).
  • Importantly, all patients with metastatic diseases expressed SNCG in their primary tumors (15/15, 100%).
  • Consistent with the IHC results, RT-PCR assays demonstrate that SNCG mRNA is highly expressed in the tumor tissue of advanced hepatocellular carcinomas.
  • To determine whether demethylation of SNCG is an early event of genetic abnormality in the process of hepatocarcinogenesis, we examined the methylation status of SNCG in 70 non-malignant cirrhotic liver samples and showed that 64.3% cirrhotic liver samples contained the partially or completely demethylated gene.
  • We further show that SNCG expression in liver cancer is not restricted to HBV- and HCV-infected tumors, implying the involvement of other hepatocarcinogenic risk factors in SNCG gene reactivation.
  • Utilizing human hepatoma-derived cell line HepG2 as an in vitro model, we demonstrate that hepatic carcinogens aflatoxin B1 and N-nitrosodimethylamine (DMN) are strong inducers of SNCG expression.
  • Collectively, these new findings suggest that SNCG protein expression in primary tumors is a strong indicator of distant metastasis and demethylation of SNCG CpG island is an early sign of genetic abnormality in liver cirrhosis preceding hepatocarcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Epigenesis, Genetic / genetics. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics. gamma-Synuclein / genetics
  • [MeSH-minor] Adult. Azacitidine / pharmacology. Base Sequence. Cell Line, Tumor. DNA Methylation. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Molecular Sequence Data. Neoplasm Metastasis. Neoplasm Proteins / genetics. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596223.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / SNCG protein, human; 0 / gamma-Synuclein; M801H13NRU / Azacitidine
  •  go-up   go-down


50. Man K, Lo CM, Xiao JW, Ng KT, Sun BS, Ng IO, Cheng Q, Sun CK, Fan ST: The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg; 2008 Jun;247(6):1049-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation.
  • OBJECTIVE: To test the hypothesis that acute phase small-for-size graft injury may promote late phase tumor recurrence after liver transplantation.
  • SUMMARY BACKGROUND DATA: Living donor liver transplantation may provide the substantial intention-to-treat survival advantage for liver cancer patients.
  • However, liver grafts from live donors are almost always small for size for adult recipients.
  • Besides, tumor recurrence and metastasis after living donor liver transplantation have been reported.
  • METHOD: An orthotopic Buffalo rat liver transplantation model using whole (100%, group W) and small-for-size grafts (50%, group S) was applied.
  • Hepatoma cells were injected into the grafts after reperfusion.
  • Comparison was made as regards acute phase graft injury and tumor growth together with cell proliferation (Ki67), angiogenesis (vascular endothelial growth factor), stellate cell activation (alpha-smooth muscle actin), and cell signaling pathway related to migration and invasion (Rac, rho-associated, coiled-coil containing protein kinase, and proline-rich tyrosine kinase 2).
  • RESULTS: Liver tumors developed earlier and faster in group S with significantly greater tumor burden [hepatic replacement area: 61%; range, 47%-72%; vs. 18%; 12%-27%; P = 0.001] and tumor cell proliferation (92% vs. 59%; P = 0.0021) in a more invasive growth pattern with a higher incidence of venous invasion (91.7% vs. 25%; P = 0.003) and more frequent hepatic stellate cell activation.
  • CONCLUSION: Significant activation of cell signaling pathways leading to tumor invasion and migration in small-for-size liver grafts promotes tumor growth and metastasis after liver transplantation.
  • [MeSH-major] Acute-Phase Reaction / metabolism. Acute-Phase Reaction / pathology. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Animals. Enzyme-Linked Immunosorbent Assay. Graft Survival. Intercellular Signaling Peptides and Proteins / metabolism. Liver / metabolism. Liver / pathology. Male. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Organ Size. Rats. Signal Transduction. Statistics, Nonparametric. Vascular Endothelial Growth Factor A / blood


51. Gondeau C, Pichard-Garcia L, Maurel P: Cellular models for the screening and development of anti-hepatitis C virus agents. Pharmacol Ther; 2009 Oct;124(1):1-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many different models based on different forms of virions and hepatoma or other cell types have been described including virus-like particles, pseudotyped particles, subgenomic and full length replicons, virion productive replicons, immortalised hepatocytes, fetal and adult primary human hepatocytes.
  • This review focuses on these different cellular models, their advantages and disadvantages at the biological and experimental levels, and their respective use for evaluating the effect of antiviral molecules on different steps of HCV biology including virus entry, replication, particles generation and excretion, as well as on the modulation by the virus of the host cell response to infection.

  • Genetic Alliance. consumer health - Hepatitis.
  • HAL archives ouvertes. Full text from .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19555718.001).
  • [ISSN] 1879-016X
  • [Journal-full-title] Pharmacology & therapeutics
  • [ISO-abbreviation] Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / RNA, Viral; 0 / Viral Hepatitis Vaccines
  • [Number-of-references] 337
  •  go-up   go-down


52. Zhang X, Dong N, Zhang H, You J, Wang H, Ye L: Effects of hepatitis B virus X protein on human telomerase reverse transcriptase expression and activity in hepatoma cells. J Lab Clin Med; 2005 Feb;145(2):98-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of hepatitis B virus X protein on human telomerase reverse transcriptase expression and activity in hepatoma cells.
  • In the experiments reported here, we used immunohistochemical methods to study the expression of hTERT and HBV antigens (HBsAg, HBcAg and HBxAg) in 34 cases of HCC and corresponding paratumor tissues, 30 cases of liver cirrhosis, and 6 normal livers.
  • To examine the effect of HBX on hTERT expression and activity in hepatoma cells, we transiently and stably transfected the pCMV-X plasmid cloned HBx gene into H7402 hepatoma cells, then measured the expression of c-Myc and hTERT in these cells with the use of Western-blot analysis.
  • We found that hTERT expression was 67.6%, 73.5%, and 100% in tumor, paratumor, and cirrhosis samples, respectively, but found no hTERT positivity in samples of normal liver.
  • Our data collectively demonstrate that HBX up-regulates the expression and activity of hTERT in hepatoma cells, suggesting that hTERT is associated with tumor development.
  • [MeSH-major] Carcinoma, Hepatocellular / physiopathology. Hepatitis B / physiopathology. Hepatitis B virus / genetics. Liver Neoplasms / physiopathology. Telomerase / genetics. Trans-Activators / genetics
  • [MeSH-minor] Adult. DNA-Binding Proteins. Female. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Humans. Liver Cirrhosis / physiopathology. Liver Cirrhosis / virology. Male. Middle Aged. Proto-Oncogene Proteins c-myc / genetics. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746653.001).
  • [ISSN] 0022-2143
  • [Journal-full-title] The Journal of laboratory and clinical medicine
  • [ISO-abbreviation] J. Lab. Clin. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Trans-Activators; 0 / hepatitis B virus X protein; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


53. Chen RC, Chang YC, Chen TH, Wu HM, Liou HH: Mortality in adult patients with epilepsy in Taiwan. Epileptic Disord; 2005 Sep;7(3):213-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality in adult patients with epilepsy in Taiwan.
  • To investigate mortality in adult patients with epilepsy in Taiwan, a total of 263 patients with epilepsy aged > or = 17 years, referred to the outpatient epilepsy clinic between 1 Jan and 31 December 1991, were prospectively enrolled and followed up until 31 December 2000.
  • One-third of the deaths in patients with age-at-onset between 40-59 years died of liver cirrhosis and hepatoma.
  • Hepatitis B virus infection is endemic in Taiwan, and this is closely associated with liver cirrhosis and hepatoma.
  • Whether anticonvulsants contributed to the hepatotoxicity that led to fatal liver disease in this group needs further investigation.
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Cause of Death. Cohort Studies. Female. Humans. Liver Diseases / complications. Liver Diseases / mortality. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Prospective Studies. Regression Analysis. Taiwan / epidemiology

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162430.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


54. Dunigan JT, Carr BI, Steel JL: Posttraumatic growth, immunity and survival in patients with hepatoma. Dig Dis Sci; 2007 Sep;52(9):2452-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttraumatic growth, immunity and survival in patients with hepatoma.
  • This study was designed to assess the relationship between posttraumatic growth (PTG), immunity, and survival in patients with biopsy-proven hepatocellular carcinoma (HCC).
  • The results of this study suggest that patients with greater PTG scores recover more rapidly from chemotherapy in regards to their white blood cell counts.
  • [MeSH-major] Carcinoma, Hepatocellular. Immunity, Cellular / immunology. Liver Neoplasms. Stress Disorders, Post-Traumatic / complications
  • [MeSH-minor] Adult. Aged. Biopsy. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Sex Distribution. Surveys and Questionnaires. Survival Rate. Time Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunol Today. 1990 May;11(5):170-5 [2186751.001]
  • [Cites] Psychooncology. 2001 Sep-Oct;10(5):436-43 [11536422.001]
  • [Cites] J Biol Regul Homeost Agents. 2003 Oct-Dec;17(4):322-6 [15065761.001]
  • [Cites] Ann Behav Med. 1999 Spring;21(2):111-21 [10499131.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):79-86 [11941989.001]
  • [Cites] Health Psychol. 1985;4(2):99-113 [4018006.001]
  • [Cites] J Trauma Stress. 1996 Jul;9(3):455-71 [8827649.001]
  • [Cites] Harv Rev Psychiatry. 1996 May-Jun;4(1):10-26 [9384968.001]
  • [Cites] Am Psychol. 1994 May;49(5):389-404 [8024167.001]
  • [Cites] Tumori. 1997 Jul-Aug;83(4):762-7 [9349318.001]
  • [Cites] Psychooncology. 1999 Sep-Oct;8(5):408-16 [10559800.001]
  • [Cites] Med Hypotheses. 1996 Jun;46(6):551-5 [8803940.001]
  • [Cites] South Med J. 2002 Dec;95(12):1429-34 [12597312.001]
  • [Cites] Acta Oncol. 1996;35(1):31-7 [8619937.001]
  • [Cites] Hepatogastroenterology. 1990 Oct;37(5):465-8 [2174825.001]
  • [Cites] Health Psychol. 2001 May;20(3):176-85 [11403215.001]
  • [Cites] J Psychosom Res. 2004 Jan;56(1):1-8 [14987957.001]
  • [Cites] J Immunol. 1985 Aug;135(2 Suppl):827s-833s [3874239.001]
  • [Cites] Psychoneuroendocrinology. 1990;15(5-6):435-51 [2101965.001]
  • [Cites] Psychol Bull. 1996 May;119(3):488-531 [8668748.001]
  • (PMID = 17417728.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Alali J, Ramji A, Ho JK, Scudamore CH, Erb SR, Cheung E, Kopit B, Bannon CA, Chung SW, Soos JG, Buczkowski AK, Brooks EM, Steinbrecher UP, Yoshida EM: Liver transplant candidacy unsuitability: a review of the British Columbia experience. Can J Gastroenterol; 2006 Feb;20(2):95-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplant candidacy unsuitability: a review of the British Columbia experience.
  • BACKGROUND: Every centre has contraindications to liver transplantation and declares patients unsuitable for medical or nonmedical reasons.
  • METHODS: A retrospective chart review was completed from 1997 to 2001, inclusive of all patients referred for liver transplant to the British Columbia Transplant Society who were declared unsuitable for transplantation, as well as the reasons for unsuitability.
  • The most common primary liver disease was hepatitis C (n=53, 35%), followed by alcoholic liver disease (n=35, 24%) and autoimmune liver diseases (n=23, 16%).
  • Medical contraindications constituted 74 patients (49.0%) and the most common reasons for unsuitability were no need of a liver transplant (29 patients [39%]), exclusion due to hepatoma or extrahepatic malignancy (20 patients [27%]) and multisystem failure (12 patients [16%]).
  • [MeSH-major] Liver Diseases / surgery. Liver Transplantation / contraindications. Patient Selection
  • [MeSH-minor] Adolescent. Adult. Aged. British Columbia. Comorbidity. Female. Hepatitis C / surgery. Humans. Liver Diseases, Alcoholic / epidemiology. Liver Diseases, Alcoholic / surgery. Male. Middle Aged. Social Support

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Transpl. 2000 Jan;6(1):122-35 [10648593.001]
  • [Cites] Transplantation. 2000 Nov 15;70(9):1335-42 [11087149.001]
  • [Cites] Can J Gastroenterol. 2000 Nov;14(10):851-5 [11111107.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1839-47 [12454841.001]
  • [Cites] Dig Dis Sci. 1986 May;31(5):468-75 [3009109.001]
  • [Cites] Am J Gastroenterol. 1993 Sep;88(9):1337-42 [8362826.001]
  • [Cites] Clin Liver Dis. 1997 Aug;1(2):247-61, vii [15562567.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Liver Transpl Surg. 1996 Mar;2(2):148-53 [9346641.001]
  • [Cites] Can J Gastroenterol. 1998 Apr;12(3):209-15 [9582546.001]
  • [Cites] Transplantation. 1999 Jun 27;67(12):1562-8 [10401763.001]
  • [Cites] Gut. 1999 Sep;45(3):421-6 [10446113.001]
  • [Cites] Hepatology. 1995 Jan;21(1):140-4 [7806148.001]
  • (PMID = 16482235.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2538970
  •  go-up   go-down


56. Aydinli M, Harmanci O, Ersoy O, Iskit AT, Ozcebe O, Abbasoglu O, Bayraktar Y: Two unusual cases with Wilson's disease: hepatoma and fulminant hepatitis treated with plasma exchange. J Natl Med Assoc; 2006 Dec;98(12):1989-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two unusual cases with Wilson's disease: hepatoma and fulminant hepatitis treated with plasma exchange.
  • Alpha-fetoprotein level was found elevated and computed tomography showed a 3.5-cm liver mass.
  • Hepatocellular carcinoma was diagnosed.
  • Radiofrequency ablation and liver transplantation were performed successfully.
  • To conclude, although hepatoma is rarely seen in Wilson's disease, patients should be examined regularly to diagnose it in a treatable stage.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepatolenticular Degeneration / complications. Liver Failure, Acute / etiology. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Female. Humans. Liver Transplantation. Male. Plasma Exchange

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Wilson Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1995 Oct;23(4):373-81 [8655953.001]
  • [Cites] Transfusion. 1998 Apr;38(4):327-31 [9595013.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Ann Intern Med. 1999 Dec 7;131(11):866 [10610638.001]
  • [Cites] Q J Med. 1989 Mar;70(263):253-63 [2602537.001]
  • [Cites] Intern Med. 2003 Oct;42(10):967-70 [14606709.001]
  • [Cites] Gastroenterology. 1983 Jan;84(1):161-7 [6847842.001]
  • [Cites] Gut. 1983 Aug;24(8):767-71 [6307837.001]
  • [Cites] QJM. 2003 Sep;96(9):657-62 [12925721.001]
  • (PMID = 17225847.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2569669
  •  go-up   go-down


57. Kaneki M: [Protective effects of vitamin K against osteoporosis and its pleiotropic actions]. Clin Calcium; 2006 Sep;16(9):1526-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accumulated evidence indicates that subclinical non-hemostatic vitamin K deficiency in extrahepatic tissues, particularly in bone, exists widely in the otherwise healthy adult population.
  • Moreover, therapeutic potential of vitamin K(2) as an anti-hepatoma drug has been recently highlighted.
  • Most of the new biological functions of vitamin K in bone and hepatoma cells are considered to be attributable to promotion of gamma-carboxylation of glutamic acid residues in vitamin K-dependent proteins, which is shared by both vitamins K(1) and K(2).
  • [MeSH-minor] 1-Carboxyglutamic Acid / metabolism. Antioxidants. Carcinoma, Hepatocellular / prevention & control. Fractures, Bone / etiology. Fractures, Bone / prevention & control. Humans. Liver Neoplasms / prevention & control. Receptors, Steroid / genetics. Soy Foods. Transcription, Genetic. Vitamin K 1. Vitamin K 2 / therapeutic use

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Vitamin K.
  • Hazardous Substances Data Bank. PHYTONADIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951479.001).
  • [ISSN] 0917-5857
  • [Journal-full-title] Clinical calcium
  • [ISO-abbreviation] Clin Calcium
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Receptors, Steroid; 0 / pregnane X receptor; 11032-49-8 / Vitamin K 2; 12001-79-5 / Vitamin K; 53445-96-8 / 1-Carboxyglutamic Acid; 84-80-0 / Vitamin K 1
  • [Number-of-references] 20
  •  go-up   go-down


58. Lu Y, Wu LQ, Li CS, Wang SG, Han B: Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. Hepatobiliary Pancreat Dis Int; 2008 Apr;7(2):174-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis.
  • BACKGROUND: Transforming growth factors (TGF)-beta1, TGF-betaR2 and Smad4 belong to the TGF family, and play important roles in carcinogenesis and the development of carcinoma, especially hepatocellular carcinoma (HCC).
  • TGF-beta1 is a multipotent polypeptide, which inhibits the growth of epithelial cells including hepatoma cell lines and hepatocytes by inducing apoptosis.
  • The positive expression of Smad4 and TGF-betaR2 was 34.04% and 59.57% respectively in the carcinoma specimens.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Transforming Growth Factors / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Disease Progression. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18397854.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 76057-06-2 / Transforming Growth Factors
  •  go-up   go-down


59. Di Stefano DR, de Baere T, Denys A, Hakime A, Gorin G, Gillet M, Saric J, Trillaud H, Petit P, Bartoli JM, Elias D, Delpero JR: Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology; 2005 Feb;234(2):625-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver resection was planned for metastases (n = 137), hepatocarcinoma (n = 31), cholangiocarcinoma (n = 15), fibrolamellar hepatoma (n = 1), and benign disease (n = 4).
  • Complications included thrombosis of the portal vein feeding the future remnant liver (n = 1); migration of emboli in the portal vein feeding the future remnant liver, which necessitated angioplasty (n = 2); hemoperitoneum (n = 1); rupture of a metastasis in the gallbladder (n = 1); transitory hemobilia (n = 1); and transient liver failure (n = 6).
  • Among the 187 patients in whom PPVE was technically successful, there was a significant difference (P < .001) between the occurrence of liver failure after PPVE in patients with cirrhosis (five of 30) and those without (one of 157).
  • Sixteen liver resections were cancelled due to cancer progression (n = 12), insufficient hypertrophy of the nonembolized liver (n = 3), and complete portal thrombosis (n = 1).
  • CONCLUSION: PPVE is a safe adjuvant technique for hypertrophy of the initially insufficient liver reserve.
  • Post-PPVE transient liver failure is more common in patients with cirrhosis than in those without cirrhosis.
  • [MeSH-major] Embolization, Therapeutic / adverse effects. Hepatectomy. Liver Neoplasms / surgery. Preoperative Care / adverse effects
  • [MeSH-minor] Acrylates / therapeutic use. Adolescent. Adult. Aged. Cholangiocarcinoma / surgery. Disease Progression. Female. Hematoma / etiology. Hemobilia / etiology. Humans. Iodized Oil / therapeutic use. Liver Cirrhosis / complications. Liver Diseases / etiology. Liver Diseases / surgery. Liver Failure / etiology. Male. Middle Aged. Portal Vein. Retrospective Studies. Thrombosis / etiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. n-Butyl acrylate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2004.
  • (PMID = 15591428.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylates; 705NM8U35V / n-butyl acrylate; 8001-40-9 / Iodized Oil
  •  go-up   go-down


60. Lau CI, Wang HC, Hsu WC: Hypoglycemic encephalopathy as the initial presentation of hepatic tumor: a case report. Neurologist; 2010 May;16(3):206-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A previously healthy 32-year-old man presenting with acute change in consciousness was found to have hepatoma related hypoglycemia.
  • CONCLUSION: This case highlights the importance of a hepatic evaluation in, otherwise, unexplained hypoglycemic coma in high prevalence areas of hepatocellular carcinoma such as the Asian-Pacific region.
  • [MeSH-major] Brain Diseases, Metabolic / etiology. Brain Diseases, Metabolic / physiopathology. Carcinoma, Hepatocellular / complications. Hypoglycemia / etiology. Hypoglycemia / physiopathology. Liver Neoplasms / complications
  • [MeSH-minor] Adult. Asian Continental Ancestry Group. Biomarkers, Tumor / analysis. Blood Glucose / metabolism. Brain / metabolism. Brain / physiopathology. Glucose / therapeutic use. Hepatitis B / complications. Hepatitis B / ethnology. Humans. Male. Prognosis. Taiwan / epidemiology. Taiwan / ethnology. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatic encephalopathy.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445433.001).
  • [ISSN] 2331-2637
  • [Journal-full-title] The neurologist
  • [ISO-abbreviation] Neurologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Glucose; IY9XDZ35W2 / Glucose
  •  go-up   go-down


61. Chiarakul S, Eunumjitkul K, Vuttiopas S, Vorapimol AR, Kaewkungwal J, Poovorawan Y: Seroprevalence and risk factors of hepatitis B virus infection among health care workers at the Institute of Neurology. J Med Assoc Thai; 2007 Aug;90(8):1536-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The significant risk factors included not having received the hepatitis B vaccine, male gender, past history of jaundice, viral hepatitis, family history of hepatoma, spouse with hepatitis B, and duration of employment in a clinical environment exceeding 5 years.
  • [MeSH-minor] Adult. Female. Hepatitis B Antibodies / blood. Hepatitis B Surface Antigens / blood. Humans. Infectious Disease Transmission, Patient-to-Professional. Male. Middle Aged. Risk Factors. Seroepidemiologic Studies. Thailand / epidemiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926982.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Hepatitis B Antibodies; 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


62. Phillips A, Hood SR, Gibson GG, Plant NJ: Impact of transcription factor profile and chromatin conformation on human hepatocyte CYP3A gene expression. Drug Metab Dispos; 2005 Feb;33(2):233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent data have made it increasingly clear that the gene expression profile of a cell system, and its alteration in response to external stimuli, is highly dependent on both the higher order chromatin structure of the genome and the interaction of gene products in interpreting stimuli.
  • To further explore this phenomenon, we have examined the role of both of these factors in controlling xenobiotic-mediated gene expression changes in primary and transformed human hepatocytes (HuH7).
  • Using quantitative polymerase chain reaction, expression levels of several transcription factors implicated in the liver-specific regulation of the CYP3A gene family were examined in human adult and fetal liver RNA samples.
  • These expression profiles were then compared with those obtained from both primary and transformed human hepatocytes, showing that, in general, cultured cells exhibit a distinct profile compared with either the fetal or adult samples.
  • Whereas exposure to these compounds elicited a dose-dependent increase in CYP3A transcription in primary hepatocytes, no alteration in expression levels was observed for the hepatoma cell line HuH7.
  • Alteration in the expression levels of pregnane X receptor and chicken ovalbumin upstream promoter transcription factor I, and the disruption of higher order chromatin within HuH7 cells altered CYP3A expression and/or activation by xenobiotics toward that observed in primary hepatocytes.
  • [MeSH-minor] Adult. Aged. Cell Line. Cytochrome P-450 CYP3A. Female. Fetus / enzymology. Humans. Male. Middle Aged. Protein Conformation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15523048.001).
  • [ISSN] 0090-9556
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / Transcription Factors; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cytochrome P-450 CYP3A; EC 1.5.- / Oxidoreductases, N-Demethylating
  •  go-up   go-down


63. Miura N, Osaki Y, Nagashima M, Kohno M, Yorozu K, Shomori K, Kanbe T, Oyama K, Kishimoto Y, Maruyama S, Noma E, Horie Y, Kudo M, Sakaguchi S, Hirooka Y, Ito H, Kawasaki H, Hasegawa J, Shiota G: A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterol; 2010;10:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel biomarker TERTmRNA is applicable for early detection of hepatoma.
  • BACKGROUNDS: We previously reported a highly sensitive method for serum human telomerase reverse transcriptase (hTERT) mRNA for hepatocellular carcinoma (HCC).
  • METHODS: In 638 subjects including 303 patients with HCC, 89 with chronic hepatitis (CH), 45 with liver cirrhosis (LC) and 201 healthy individuals, we quantified serum hTERTmRNA using the real-time RT-PCR.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / diagnosis. Early Detection of Cancer / methods. Liver Neoplasms / diagnosis. RNA, Messenger / genetics. Telomerase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. ROC Curve. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Stat Med. 1991 Jul;10(7):1075-88 [1876796.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jan;93(1):56-62 [9062581.001]
  • [Cites] Int J Cancer. 1997 Apr 22;74(2):141-7 [9133446.001]
  • [Cites] Br J Cancer. 1997;76(5):628-33 [9303362.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1561-7 [10102626.001]
  • [Cites] Pathol Int. 1999 Jun;49(6):491-9 [10469391.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):1961-5 [10473072.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3205-9 [15867214.001]
  • [Cites] Hepatology. 2006 Jun;43(6):1284-94 [16729333.001]
  • [Cites] Acta Gastroenterol Belg. 2006 Apr-Jun;69(2):230-5 [16929622.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 29;351(4):853-9 [17094946.001]
  • [Cites] Cancer Sci. 2006 Dec;97(12):1366-73 [17052260.001]
  • [Cites] Oncol Rep. 2007 Mar;17(3):541-8 [17273731.001]
  • [Cites] Hepatology. 2007 Apr;45(4):968-76 [17393506.001]
  • [Cites] Biochem Pharmacol. 2007 Jun 1;73(11):1703-14 [17321502.001]
  • [Cites] Anticancer Res. 2007 Mar-Apr;27(2):1207-12 [17465264.001]
  • [Cites] Biol Pharm Bull. 2007 Aug;30(8):1400-6 [17666793.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2304-10 [17713555.001]
  • [Cites] J Leukoc Biol. 2007 Nov;82(5):1174-84 [17715360.001]
  • [Cites] Mol Cell. 2007 Oct 26;28(2):315-27 [17964269.001]
  • [Cites] Eur J Cell Biol. 2007 Dec;86(11-12):763-80 [17198740.001]
  • [Cites] Exp Mol Med. 2007 Oct 31;39(5):641-52 [18059140.001]
  • [Cites] FASEB J. 2008 Feb;22(2):622-32 [17898088.001]
  • [Cites] Hepatology. 2008 Dec;48(6):2047-63 [19003900.001]
  • [Cites] Ann N Y Acad Sci. 2006 May;1067:443-7 [16804024.001]
  • [Cites] J Pathol. 1999 Oct;189(2):213-8 [10547577.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(4):496-502 [10717526.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3823-6 [11051224.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Sep;15(9):1064-70 [11059939.001]
  • [Cites] Arch Surg. 2000 Nov;135(11):1334-9 [11074892.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):162-71 [11410861.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Jul;17(7):772-8 [12121507.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1212-7 [12142376.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1647-53 [12324479.001]
  • [Cites] Oncology. 2003;64(4):430-4 [12759542.001]
  • [Cites] Cell. 2003 Jun 27;113(7):881-9 [12837246.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3004-11 [12912949.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1008-13 [12942569.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Oct;18(10):1168-74 [12974904.001]
  • [Cites] Hepatology. 2003 Dec;38(6):1540-51 [14647065.001]
  • [Cites] Cell Transplant. 2003;12(8):897-906 [14763510.001]
  • [Cites] World J Gastroenterol. 2004 Jul 15;10(14):2147-9 [15237456.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):44-50 [15305374.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6622-6 [3413114.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1050-5 [8635122.001]
  • (PMID = 20482774.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2881114
  •  go-up   go-down


64. Caja L, Ortiz C, Bertran E, Murillo MM, Miró-Obradors MJ, Palacios E, Fabregat I: Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Cell Signal; 2007 Apr;19(4):683-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis.
  • Indeed, escaping from the TGF-beta suppressor actions might be a prerequisite for liver tumour progression.
  • In this work we show that TGF-beta plays a dual role in regulating apoptosis in FaO rat hepatoma cells, since, in addition to its pro-apoptotic effect, TGF-beta also activates survival signals, such as AKT, the epidermal growth factor receptor (EGFR) being required for its activation.
  • In contrast, TGF-beta does not activate AKT in adult hepatocytes, which correlates with lack of EGFR transactivation and no response to EGFR inhibitors.
  • Although TGF-beta induces TGF-alpha and HB-EGF in adult hepatocytes, these cells show very low expression of TACE/ADAM 17 (TNF-alpha converting enzyme), which is required for EGFR ligand proteolysis and activation.
  • Furthermore, adult hepatocytes do not undergo EMT processes in response to TGF-beta, which might be due, at least in part, to the fact that F-actin re-organization induced by TGF-beta in FaO cells require the EGFR pathway.
  • Finally, results indicate that EGFR transactivation does not block TGF-beta-induced cell cycle arrest in FaO cells, but must be interfering with the pro-apoptotic signalling.
  • In conclusion, TGF-beta is a suppressor factor for adult quiescent hepatocytes, but not for hepatoma cells, where it plays a dual role, both suppressing and promoting carcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Hepatocytes / drug effects. Hepatocytes / metabolism. Signal Transduction / drug effects. Transforming Growth Factor beta / pharmacology
  • [MeSH-minor] ADAM Proteins / genetics. ADAM Proteins / metabolism. Actins / metabolism. Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Enzyme Activation / drug effects. Epithelial Cells / cytology. Epithelial Cells / drug effects. Humans. Male. Mesoderm / cytology. Mesoderm / drug effects. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Rats, Wistar. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Transcriptional Activation / drug effects. src-Family Kinases / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17055226.001).
  • [ISSN] 0898-6568
  • [Journal-full-title] Cellular signalling
  • [ISO-abbreviation] Cell. Signal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.2 / src-Family Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
  •  go-up   go-down


65. Dvorák Z, Vrzal R, Starha P, Klanicová A, Trávnícek Z: Effects of dinuclear copper(II) complexes with 6-(benzylamino)purine derivatives on AhR and PXR dependent expression of cytochromes P450 CYP1A2 and CYP3A4 genes in primary cultures of human hepatocytes. Toxicol In Vitro; 2010 Mar;24(2):425-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of dinuclear copper(II) complexes with 6-(benzylamino)purine derivatives on AhR and PXR dependent expression of cytochromes P450 CYP1A2 and CYP3A4 genes in primary cultures of human hepatocytes.
  • As models, primary cultures of human hepatocytes and human hepatoma cells HepG2 transiently transfected with a plasmid containing dioxin-responsive element fused to the luciferase reporter gene (DRE-LUC) have been chosen.
  • It has been found that the tested complexes 1-6 did not significantly induce the expression of CYP1A2 and CYP3A4 mRNAs in the concentration range of 0.1-10.0microM, in three different primary human hepatocyte cultures after 24h of the treatment.
  • [MeSH-minor] Adult. Aged. Cells, Cultured. Gene Expression Regulation, Enzymologic / drug effects. Hepatocytes / drug effects. Hepatocytes / metabolism. Humans. Male. Middle Aged. Molecular Structure. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Hazardous Substances Data Bank. BENZYLADENINE .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19854261.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzyl Compounds; 0 / Purines; 0 / RNA, Messenger; 0 / Receptors, Aryl Hydrocarbon; 0 / Receptors, Steroid; 0 / pregnane X receptor; 789U1901C5 / Copper; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / CYP1A2 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1A2; EC 1.14.14.1 / Cytochrome P-450 CYP3A; KXG6A989PS / benzylaminopurine
  •  go-up   go-down


66. Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y, Aozasa K, Uyama H, Nakamura H, Monden M: Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol; 2007 Jul;14(7):2141-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma.
  • BACKGROUND: Hepatoma-derived growth factor (HDGF) is thought to play an important role in the development and progression of carcinomas.
  • In the present study, association of HDGF expression with recurrence and prognosis of esophageal carcinoma (EC) was examined.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Esophageal Neoplasms / metabolism. Intercellular Signaling Peptides and Proteins / biosynthesis. Neoplasm Recurrence, Local / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473954.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / hepatoma-derived growth factor
  •  go-up   go-down


67. Homer VM, Marais AD, Charlton F, Laurie AD, Hurndell N, Scott R, Mangili F, Sullivan DR, Barter PJ, Rye KA, George PM, Lambert G: Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis; 2008 Feb;196(2):659-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We overexpressed those mutants in hepatoma cells and found that both S127R and D129G have reduced autocatalytic activity compared with wild-type PCSK9, whereas the A168E mutant is processed normally.
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Amino Acid Substitution. Animals. Apolipoprotein B-100 / genetics. Cohort Studies. Female. Humans. Middle Aged. Molecular Sequence Data. Mutation, Missense. New Zealand. Pedigree. Proprotein Convertases. Receptors, LDL / genetics. Sequence Alignment. South Africa

  • Genetic Alliance. consumer health - Familial Hypercholesterolemia.
  • Genetic Alliance. consumer health - Hypercholesterolemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765244.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Apolipoprotein B-100; 0 / Receptors, LDL; EC 3.4.- / Proprotein Convertases; EC 3.4.21.- / PCSK9 protein, human; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


68. Nattermann J, Vogel M, Berg T, Danta M, Axel B, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grünhage F, Rausch M, Nischalke HD, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U, Kompetenznetz HIV/AIDS: Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology; 2007 Oct;46(4):1016-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Signal transducer and activator of transcription three phosphorylation was analyzed by Western blot in HCV core-transfected human hepatoma cell line (HUH7) cells.
  • [MeSH-minor] Acute Disease. Adult. Aged. Cell Line, Tumor. Chronic Disease. Dose-Response Relationship, Drug. Drug Therapy, Combination. Female. Genotype. Humans. Interferon-alpha / therapeutic use. Male. Middle Aged. Polyethylene Glycols / therapeutic use. Recombinant Proteins. Ribavirin / therapeutic use. STAT3 Transcription Factor / genetics. STAT3 Transcription Factor / metabolism. Treatment Outcome


69. Kaneki M, Hosoi T, Ouchi Y, Orimo H: Pleiotropic actions of vitamin K: protector of bone health and beyond? Nutrition; 2006 Jul-Aug;22(7-8):845-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accumulated evidence indicates that subclinical non-hemostatic vitamin K deficiency in extrahepatic tissues, particularly in bone and possibly in vasculature, exists widely in the otherwise healthy adult population.
  • Most of the new biological functions of vitamin K in bone, vasculature, and hepatoma cells are considered attributable to promotion of gamma-carboxylation of glutamic acid residues in vitamin K-dependent proteins, which is shared by vitamins K1 and K2.
  • [MeSH-minor] Animals. Atherosclerosis / prevention & control. Calcinosis. Carcinoma, Hepatocellular / prevention & control. Humans. Liver Neoplasms / prevention & control. Osteoporosis / drug therapy. Osteoporosis / epidemiology. Osteoporosis / prevention & control. Vitamin K 1 / therapeutic use. Vitamin K 2 / analogs & derivatives. Vitamin K 2 / therapeutic use. Vitamin K Deficiency / complications. Vitamin K Deficiency / physiopathology

  • MedlinePlus Health Information. consumer health - Vitamin K.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PHYTONADIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16815498.001).
  • [ISSN] 0899-9007
  • [Journal-full-title] Nutrition (Burbank, Los Angeles County, Calif.)
  • [ISO-abbreviation] Nutrition
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11032-49-8 / Vitamin K 2; 12001-79-5 / Vitamin K; 27Y876D139 / menatetrenone; 84-80-0 / Vitamin K 1
  • [Number-of-references] 78
  •  go-up   go-down


70. Silberhumer GR, Hetz H, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Soliman T, Steininger R, Muehlbacher F, Berlakovich GA: Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival? Transpl Int; 2006 Apr;19(4):275-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Model for end-stage liver disease (MELD) score has emerged as a useful tool in predicting mortality in patients awaiting liver transplantation.
  • From 1997 to 2003, 621 adult patients with end-stage liver disease were listed for orthotopic liver transplantation (OLT).
  • Patients suffering from hepatoma were excluded from analysis (113 patients).
  • [MeSH-major] Liver Failure / mortality. Liver Failure / surgery. Liver Transplantation / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Models, Biological. Resource Allocation. Risk Factors. Survival Rate. Tissue and Organ Procurement. Waiting Lists

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Transpl Int. 2006 Apr;19(4):270-4 [16573541.001]
  • (PMID = 16573542.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Guguen-Guillouzo C, Corlu A, Guillouzo A: Stem cell-derived hepatocytes and their use in toxicology. Toxicology; 2010 Mar 30;270(1):3-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell-derived hepatocytes and their use in toxicology.
  • Besides primary hepatocytes and transformed liver cell lines, stem cells either isolated from embryos or adult tissues or obtained by reprogramming somatic cells are emerging as a new potential source of unlimited numbers of hepatocytes.
  • Presently, only hepatocyte-like cells expressing low levels of liver-specific markers, especially drug metabolizing and detoxifying enzymes, are usually obtained, making them still unsuitable as metabolically competent cells for toxicity studies.
  • The only exceptions are some hepatoma cell lines, particularly the HepaRG cell line that can differentiate from a bipotent progenitor stage to attain the functional capacity of normal adult hepatocytes in primary culture without losing the indefinite growth property of transformed cells.
  • [MeSH-minor] Adult. Animals. Cell Line, Tumor. Embryonic Stem Cells / drug effects. Female. Humans. Hybrid Cells. Liver / pathology. Liver Neoplasms / pathology. Pregnancy

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19815049.001).
  • [ISSN] 1879-3185
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 60
  •  go-up   go-down


72. Modanlou KA, Oliver DA, Grossman BJ: Liver donor's age and recipient's serum creatinine predict blood component use during liver transplantation. Transfusion; 2009 Dec;49(12):2645-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver donor's age and recipient's serum creatinine predict blood component use during liver transplantation.
  • BACKGROUND: Excessive use of blood components during liver transplantation should be avoided because it has been associated with poor outcomes and it may stress blood bank resources.
  • STUDY DESIGN AND METHODS: To determine preoperative predictors of excessive transfusion requirements in patients undergoing liver transplantation, the clinical records of 126 consecutive adult patients undergoing primary liver transplantation were retrospectively reviewed.
  • Univariate analyses of the following predictor variables were performed: recipient age, sex, ethnicity, height/weight, Model for End Stage Liver Disease score, year of transplant, previous abdominal surgery, hepatoma, wait-list time, standard recipient laboratory values obtained immediately before transplantation, cold ischemia time, donor age, sex, and height/weight.
  • ] CONCLUSION: Liver donor's age and recipient's SCr are important in preoperatively predicting blood use during liver transplantation.
  • [MeSH-major] Blood Component Transfusion. Blood Loss, Surgical / prevention & control. Creatinine / blood. Liver Transplantation. Tissue Donors
  • [MeSH-minor] Adult. Age Factors. Aged. Blood Banks. Erythrocyte Count. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Preoperative Care. Retrospective Studies


73. Cheng Y, Seet BL, Ong CS, Wasser S, Tan TM, Peter FJ, Lim SG: Are in vitro hepatitis B core promoter mutations important for clinical alterations in viral load? Antiviral Res; 2006 Mar;69(3):142-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro studies of HBV core promoter mutations in hepatoma cell lines suggest that some mutations in core promoter transcription factor binding sites result in reduced core promoter activity and viral replication.
  • [MeSH-minor] Adult. Binding Sites. Consensus Sequence. DNA Mutational Analysis. DNA, Viral / chemistry. DNA, Viral / genetics. Genotype. Hepatitis B e Antigens / blood. Humans. Sequence Analysis, DNA. Virus Replication / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406140.001).
  • [ISSN] 0166-3542
  • [Journal-full-title] Antiviral research
  • [ISO-abbreviation] Antiviral Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Core Antigens; 0 / Hepatitis B e Antigens
  •  go-up   go-down


74. Fujimoto T, Tomizawa M, Yokosuka O: SiRNA of frizzled-9 suppresses proliferation and motility of hepatoma cells. Int J Oncol; 2009 Oct;35(4):861-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SiRNA of frizzled-9 suppresses proliferation and motility of hepatoma cells.
  • Frizzled (Fz), a receptor of Wnt ligands, plays key roles in liver carcinogenesis.
  • Its expression was analyzed as part of a search for a target of molecular therapy for hepatocellular carcinoma (HCC) and hepatoblastoma (HB).
  • Fz genes were analyzed by RT-PCR in HCC cell lines HLE, HLF, PLC/PRF/5, Huh-7 and Hep3B, HB cell lines Huh-6 and HepG2, HeLa cells, human normal fetal and adult liver.
  • Five days after transfection, cell proliferation was analyzed by MTS assay and cell motility by wound assay with H&E staining.
  • Fz9-siRNA decreased the expression of Fz9 gene in all cell lines.
  • MTS assay showed that Fz9-siRNA significantly suppressed cell proliferation and cell motility in all cell lines.
  • Cleaved caspase-3 did not appear and apoptosis was not observed in any of the cell lines tested.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cell Movement. Cell Proliferation. Frizzled Receptors / metabolism. Liver Neoplasms / metabolism. RNA Interference. RNA, Small Interfering / metabolism. Receptors, G-Protein-Coupled / metabolism
  • [MeSH-minor] Adult. Apoptosis. Blotting, Western. Caspase 3 / metabolism. Cyclin D1 / metabolism. Down-Regulation. HeLa Cells. Humans. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Transfection

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Guide to Pharmacology. gene/protein/disease-specific - FZD9 - data and references .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19724923.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / FZD3 protein, human; 0 / Frizzled Receptors; 0 / RNA, Small Interfering; 0 / Receptors, G-Protein-Coupled; 136601-57-5 / Cyclin D1; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


75. Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inui A, Jang JJ, Su IJ: Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci; 2009 Dec;100(12):2249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although many studies on the risk factors and their carcinogenesis in adult hepatocellular carcinoma (HCC) have been reported, they remain poorly understood in childhood HCC.
  • The HBV pre-S2 deletion mutant at nt 4-57 which has a CD8 T-cell epitope could be responsible for the emergence and aggressive outcome of childhood HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Gene Deletion. Hepatitis B Surface Antigens / genetics. Hepatitis B virus / genetics. Liver Neoplasms / etiology. Protein Precursors / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719772.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Protein Precursors; 0 / presurface protein 2, hepatitis B surface antigen
  •  go-up   go-down


76. Chang-Chien CH, Ding HT, Liu C, Yang CS: Vibrio infection associated with finning injury of the hand. Injury; 2007 May;38(5):614-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In our group of nine patients, seven had concurrent hepatoma, diabetes mellitus, cirrhosis, chronic renal insufficiency or the effects of long-term steroid use; three had wound infections manifested by cellulitis or tenosynovitis and six had life-threatening necrotising soft-tissue infections.
  • [MeSH-minor] Adult. Aged. Animals. Female. Fishes. Humans. Length of Stay. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hand Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945371.001).
  • [ISSN] 0020-1383
  • [Journal-full-title] Injury
  • [ISO-abbreviation] Injury
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


77. Aucejo F, Kim R, Zein N, Quintini C, Uso TD, Lopez R, Eghtesad B, Fung J, Miller C, Yerian L: Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl; 2009 Feb;15(2):169-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria.
  • Hepatocellular carcinoma (HCC) is a highly vascular tumor.
  • VEGF mediates its angiogenic effects through multiple receptors including VEGF receptor 2 (VEGFr2, KDR/FLK-1), The distribution and clinical significance of VEGFr2 expression in HCC and cirrhotic liver in the setting of liver transplantation have not been tissue site specific evaluated.
  • Immunohistochemical staining for VEGFr2 was performed in 78 liver explants from patients with HCC undergoing liver transplantation.
  • VEGFr2 levels in HCC were significantly increased compared to adjacent, nontumorous cirrhotic liver areas (P < 0.05).
  • However, VEGFr2 levels were significantly higher in the arteries of non-tumorous liver in patients beyond Milan criteria (P < 0.05).
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Liver Cirrhosis / genetics. Liver Neoplasms / genetics. Vascular Endothelial Growth Factor Receptor-2 / biosynthesis
  • [MeSH-minor] Adult. Female. Gene Expression. Humans. Male. Up-Regulation

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 AASLD.
  • (PMID = 19177438.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


78. Sumethkul V, Ingsathit A, Jirasiritham S: Ten-year follow-up of kidney transplantation from hepatitis B surface antigen-positive donors. Transplant Proc; 2009 Jan-Feb;41(1):213-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven deaths occurred among Group 2; they were due to chronic active hepatitis (n = 5), hepatoma (n = 3), acute fibrosing cholestatic hepatitis (n = 1), and stroke (n = 2).
  • This was not associated with evidence of active liver disease.
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Cadaver. DNA, Viral / blood. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Lamivudine / therapeutic use. Middle Aged. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Survival Rate. Survivors. Time Factors


79. Bylesjö I, Wikberg A, Andersson C: Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest; 2009;69(5):612-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatoma was strikingly overrepresented.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Clinical Laboratory Techniques. Female. Heterozygote. Humans. Insurance, Disability. Male. Middle Aged. Sick Leave. Smoking. Sweden. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Acute Intermittent Porphyria.
  • Genetic Alliance. consumer health - Porphyria.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19401933.001).
  • [ISSN] 1502-7686
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Goulet F, Napa ID, Solomon L, Morin O, Islam N: Modulated expression of a nuclear-associated glycoprotein during normal rat liver development and in various hepatoma cells. Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan;30(1):159-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulated expression of a nuclear-associated glycoprotein during normal rat liver development and in various hepatoma cells.
  • Liver plays a major role in systemic detoxification and drug metabolism.
  • NF-164, a protein of 164 kDa predominantly localized in hepatocyte nuclei, was found to be present in increasing amounts during liver maturation.
  • In addition, fetal rat hepatocytes had ten times, and neonatal five times less of this protein than adult hepatocytes.
  • It was also detected in an albumin producing hepatoma cell line, but not in three other lines that have lost several differentiated functions.
  • NF-164 seems to be liver-specific, since it was not detected in rat brain, spleen, kidney, lung and bovine thymus.
  • It was purified from adult rat hepatocyte nuclei.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Gene Expression Regulation, Developmental / physiology. Hepatocytes / metabolism. Liver Neoplasms / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Age Factors. Animals. Animals, Newborn. Cell Proliferation. Cells, Cultured. Electrophoresis / methods. Electrophoresis, Polyacrylamide Gel / methods. Female. Molecular Weight. Radioimmunodetection / methods. Rats. Rats, Inbred F344. Sequence Analysis, Protein / methods. Subcellular Fractions / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16233943.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-164 protein, rat; 0 / Nuclear Proteins
  •  go-up   go-down


81. Xu CP, Ji WM, van den Brink GR, Peppelenbosch MP: Bone morphogenetic protein-2 is a negative regulator of hepatocyte proliferation downregulated in the regenerating liver. World J Gastroenterol; 2006 Dec 21;12(47):7621-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone morphogenetic protein-2 is a negative regulator of hepatocyte proliferation downregulated in the regenerating liver.
  • AIM: To characterize the expression and dynamic changes of bone morphogenetic protein (BMP)-2 in hepatocytes in the regenerating liver in rats after partial hepatectomy (PH), and examine the effects of BMP-2 on proliferation of human Huh7 hepatoma cells.
  • METHODS: Fifty-four adult male Wistar rats were randomly divided into three groups: A normal control (NC) group, a partial hepatectomized (PH) group and a sham operated (SO) group.
  • To study the effect of liver regeneration on BMP-2 expression, rats were sacrificed before and at different time points after PH or the sham intervention (6, 12, 24 and 48 h).
  • Expression and distribution of BMP-2 protein were determined in regenerating liver tissue by Western blot analysis and immunohistochemistry.
  • Effects of BMP-2 on cell proliferation of human Huh7 hepatoma cell line were assessed using an MTT assay.
  • RESULTS: In the normal liver strong BMP-2 expression was observed around the central and portal veins.
  • BMP-2 inhibited serum induced Huh7 cell proliferation.
  • CONCLUSION: BMP-2 is expressed in normal adult rat liver and negatively regulates hepatocyte proliferation.
  • [MeSH-major] Bone Morphogenetic Proteins / metabolism. Hepatocytes / cytology. Hepatocytes / metabolism. Liver Regeneration / physiology. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Animals. Bone Morphogenetic Protein 2. Carcinoma, Hepatocellular. Cell Division / drug effects. Cell Division / physiology. Cell Line, Tumor. Down-Regulation / drug effects. Down-Regulation / physiology. Humans. Liver Neoplasms. Male. Rats. Rats, Wistar

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5476-82 [7890664.001]
  • [Cites] J Biol Chem. 1991 Nov 25;266(33):22444-50 [1718994.001]
  • [Cites] Exp Cell Res. 1997 May 1;232(2):263-9 [9168801.001]
  • [Cites] Clin Orthop Relat Res. 1998 Jan;(346):26-37 [9577407.001]
  • [Cites] Bone. 1998 Jun;22(6):591-603 [9626397.001]
  • [Cites] Biofactors. 1999;9(1):11-7 [10221153.001]
  • [Cites] Oncogene. 2005 Apr 21;24(18):3028-41 [15735717.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1998-2009 [11485993.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Sep;10(9):1677-86 [11772277.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):784-7 [12679932.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G539-46 [12791600.001]
  • [Cites] J Surg Res. 2004 Apr;117(2):306-15 [15047136.001]
  • [Cites] Dev Biol. 2004 Apr 15;268(2):312-26 [15063170.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):836-47 [15459664.001]
  • [Cites] Science. 1965 Nov 12;150(3698):893-9 [5319761.001]
  • [Cites] Cancer Res. 1982 Sep;42(9):3858-63 [6286115.001]
  • [Cites] Cancer Res. 1986 May;46(5):2330-4 [3008986.001]
  • [Cites] Science. 1988 Dec 16;242(4885):1528-34 [3201241.001]
  • [Cites] Endocrinology. 1995 Oct;136(10):4293-7 [7664647.001]
  • (PMID = 17171790.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / Bmp2 protein, rat; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Proteins; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC4088043
  •  go-up   go-down


82. Masuda T, Beppu T, Horino K, Komori H, Hayashi H, Okabe H, Ootao R, Horlad H, Baba Y, Miyase S, Takamori H, Baba H: Occurrence of hepatocellular carcinoma after hepatoblastoma resection in an adult with hepatitis C virus. Hepatol Res; 2009 May;39(5):525-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of hepatocellular carcinoma after hepatoblastoma resection in an adult with hepatitis C virus.
  • In patients with no indication for a hepatic resection, the prognosis of adult hepatoblastoma is quite poor.
  • A 54-year-old man with hepatitis C virus-associated liver cirrhosis was initially treated with a hepatic resection for a hepatic tumor, 3 cm in diameter.
  • The tumor consisted of osteoid-like and cartilaginous foci, myxomatous stroma, and poorly differentiated hepatocellular carcinomatous cells and was diagnosed as a mixed epithelial and mesenchymal hepatoblastoma.
  • Two years after the first operation, multicentric hepatocellular carcinomas developed in the remnant liver and were successfully treated with a secondary hepatic resection combined with radio-frequency ablation.
  • To the best of our knowledge, the primary hepatoblastoma was the smallest such tumor reported and this is the first report of a metachronous hepatoblastoma and hepatocellular carcinoma in an adult hepatitis patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19207587.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


83. van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P, Whittle HC: Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One; 2007 Aug 15;2(8):e753
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chronic infection with hepatitis B virus (HBV) arising in childhood is associated with hepatocellular carcinoma in adult life.
  • Between 1986 and 1990, approximately 120,000 Gambian newborns were enrolled in a randomised controlled trial to assess the effectiveness of infant HBV vaccination on the prevention of hepatocellular carcinoma in adulthood.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / virology. Child. Female. Gambia. Humans. Infant. Liver Neoplasms / etiology. Liver Neoplasms / virology. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Feb 12;355(9203):561-5 [10683019.001]
  • [Cites] J Infect Dis. 2006 Jun 1;193(11):1528-35 [16652281.001]
  • [Cites] Pediatrics. 2001 Apr;107(4):626-31 [11335734.001]
  • [Cites] BMJ. 2002 Sep 14;325(7364):569 [12228132.001]
  • [Cites] Scand J Infect Dis. 2002;34(8):610-4 [12238579.001]
  • [Cites] Vaccine. 2002 Oct 4;20(29-30):3472-6 [12297392.001]
  • [Cites] Pediatr Infect Dis J. 2003 Feb;22(2):157-63 [12586980.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5782-7 [2822233.001]
  • [Cites] J Med Virol. 1988 Apr;24(4):377-84 [3367136.001]
  • [Cites] Lancet. 1991 Mar 30;337(8744):747-50 [1672389.001]
  • [Cites] J Hepatol. 1994 Aug;21(2):250-4 [7989718.001]
  • [Cites] J Infect Dis. 1997 Jun;175(6):1494-7 [9180192.001]
  • [Cites] Clin Infect Dis. 1998 Apr;26(4):933-7 [9564478.001]
  • [Cites] Vaccine. 1998 Apr;16(6):624-9 [9569474.001]
  • [Cites] J Infect Dis. 1999 Feb;179(2):489-92 [9878036.001]
  • [Cites] Vaccine. 1999 Apr 23;17(17):2162-5 [10367949.001]
  • [Cites] Vaccine. 1999 Jun 4;17(20-21):2661-6 [10418916.001]
  • [Cites] Vaccine. 1999 Aug 6;17(23-24):2946-50 [10462228.001]
  • [Cites] Vaccine. 2005 Dec 30;23(50):5792-7 [16303217.001]
  • [Cites] J Clin Virol. 2005 Dec;34 Suppl 1:S1-3 [16461208.001]
  • [Cites] Vaccine. 2000 Nov 22;19(7-8):877-85 [11115711.001]
  • (PMID = 17710152.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U190071425; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Other-IDs] NLM/ PMC1940311
  • [General-notes] NLM/ Original DateCompleted: 20070822
  •  go-up   go-down


84. Yoo HY, Thuluvath PJ: Short-term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States. Liver Int; 2005 Jun;25(3):536-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It has been suggested that the introduction of model for end-stage liver disease (MELD) for organ allocation may reduce overall graft and patient survival since elevated serum creatinine is an important predictor of poor outcome after liver transplantation.
  • OBJECTIVE: In this study, we determined the outcomes of liver transplantation before (PreMELD group, 1998-February, 2002) and after (MELD group, March-December, 2002, n = 4642) the introduction of MELD score, and examined the impact of MELD scores on the outcome in the United States (US).
  • PATIENTS & METHODS: After excluding patients for a variety of reasons (children, live-donor, fulminant liver failure, patients with hepatoma and others who received extra MELD points, multiple organ transplantation, re-transplantation, incomplete data), there were 3227 patients in the MELD group.
  • [MeSH-major] Liver Failure / mortality. Liver Transplantation / mortality. Resource Allocation / statistics & numerical data. Severity of Illness Index. Tissue and Organ Procurement / statistics & numerical data
  • [MeSH-minor] Adult. Creatinine / blood. Female. Graft Survival. Humans. Male. Middle Aged. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910490.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


85. Chiu CC, Huang YW, Chou SH, Huang GT, Chiou LL, Lee HS: Generation of a monoclonal antibody specifically reacting with undifferentiated liver progenitor cells. Hybridoma (Larchmt); 2009 Dec;28(6):435-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation of a monoclonal antibody specifically reacting with undifferentiated liver progenitor cells.
  • An adult rat liver progenitor cell line Lig-8 was established.
  • In the induction by sodium butyrate, these cells were shown to be able to differentiate into both hepatocytes and bile duct cells expressing albumin and cytokeratin-19, the markers of respective cell types.
  • It specifically stained on Lig-8 cells in the cytoplasm but not on a rat hepatoma cell line H4IIE.
  • Its immunoreaction against Lig-8 cell lysate on dot blots diminished as the concentration of sodium dodecyl sulfate (SDS) in the lysate increased to 2%, a level in the sample buffer of standard SDS-polyacrylamide gel electrophoresis (PAGE).
  • Not surprisingly, Ligab failed to detect its reacting antigen in Lig-8 cell lysate by standard SDS-PAGE-based immunoblotting.
  • This antigen is very likely a differentiation-related marker for these cells, and this monoclonal antibody may help study the molecular mechanisms of liver progenitor cell differentiation.
  • [MeSH-major] Antibodies, Monoclonal / biosynthesis. Antibodies, Monoclonal / immunology. Hybridomas / immunology. Liver / cytology. Stem Cells / immunology
  • [MeSH-minor] Animals. Butyrates. Cell Differentiation / immunology. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Immunoblotting. Microscopy, Fluorescence. Rats

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025503.001).
  • [ISSN] 1557-8348
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Butyrates
  •  go-up   go-down


86. Vay D, Rigamonti C, Vidali M, Mottaran E, Alchera E, Occhino G, Sartori M, Albano E: Anti-phospholipid antibodies associated with alcoholic liver disease target oxidized phosphatidylserine on apoptotic cell plasma membranes. J Hepatol; 2006 Jan;44(1):183-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-phospholipid antibodies associated with alcoholic liver disease target oxidized phosphatidylserine on apoptotic cell plasma membranes.
  • BACKGROUND/AIMS: Circulating anti-phospholipid antibodies (aPL) are often present in patients with alcoholic liver disease (ALD).
  • METHODS: Apoptosis was induced in HuT-78 human T-lymphoma and HepG2 hepatoma cells by, respectively, FAS ligation with CH11 monoclonal antibodies or the incubation with ethanol (400 mmol/L).
  • [MeSH-major] Antibodies, Antiphospholipid / immunology. Apoptosis / physiology. Cell Membrane / metabolism. Liver Diseases, Alcoholic / metabolism. Oxidative Stress / physiology. Phosphatidylserines / metabolism
  • [MeSH-minor] Adult. Aged. Cells, Cultured. Female. Flow Cytometry. Hepatocytes / metabolism. Hepatocytes / ultrastructure. Humans. Lipid Peroxidation / physiology. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143424.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Phosphatidylserines
  •  go-up   go-down


87. Toniutto P, Fabris C, Pirisi M: Antiviral treatment of hepatitis C. Expert Opin Pharmacother; 2006 Oct;7(15):2025-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapy of hepatitis C virus (HCV) infection may prevent progression to cirrhosis, hepatocellular carcinoma and end-stage liver disease.
  • A better understanding of the HCV genomic organisation, the elucidation of the three-dimensional structures of virally encoded enzymes and the recent development of a HCV-replicon system in human hepatoma (Huh-7) cells have led to significant advances in the development of new antiviral compounds, many of which are under evaluation in clinical trials.
  • [MeSH-minor] Adult. Humans. Logistic Models. Randomized Controlled Trials as Topic. Recombinant Proteins. Serine Proteinase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020430.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / Serine Proteinase Inhibitors; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin; 76543-88-9 / interferon alfa-2a
  • [Number-of-references] 84
  •  go-up   go-down


88. Huang Z, Liu C: [Construction and identification of the human liver-specific miR-122 expression vector]. Sheng Wu Gong Cheng Xue Bao; 2009 Apr;25(4):587-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Construction and identification of the human liver-specific miR-122 expression vector].
  • miR-122 is the most abundant miRNA in adult human liver.
  • To study the functions of miR-122 in liver disease, we amplified the precursor of human miR-122 gene by polymerase chain reaction (PCR) from the HepG2 genomic DNA, and then constructed miR-122 expression vector pLMP-miR-122. pLMP-miR-122 could overexpress mature miR-122 when human normal liver cells L-O2 and the hepatoma cells HepG2 were transfected with it.
  • These results showed that the human liver specific miR-122 expression vector was constructed successfully, and it could regulate the replication and the expression of HBV genes.
  • The plasmid pLMP-miR-122 will facilitate further studies of the functions of miR-122 in the development of liver virus infection diseases and HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Genetic Vectors / genetics. Liver Neoplasms / genetics. MicroRNAs / analysis. MicroRNAs / genetics
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Humans. Liver / metabolism. Molecular Sequence Data. Plasmids / genetics. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637636.001).
  • [ISSN] 1000-3061
  • [Journal-full-title] Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  • [ISO-abbreviation] Sheng Wu Gong Cheng Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MIRN122 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


89. Tang JQ, Fan Q, Wu WH, Jia ZC, Li H, Yang YM, Liu YC, Wan YL: Extrahepatic synthesis of coagulation factor VII by colorectal cancer cells promotes tumor invasion and metastasis. Chin Med J (Engl); 2010 Dec;123(24):3559-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Blood coagulation factor VII (FVII) is physiologically synthesized in the liver and released into the blood.
  • The FVII mRNA in 45 of 55 CRC cases, 6 colon cancer cell lines and one hepatoma cell line was measured by real-time reverse transcription-PCR (RT-PCR).
  • Transwell invasion assays were performed to evaluate the changes of cell migration and invasion of LoVo cancer cells in vitro.
  • Liver metastasis (P = 0.003) and TNM staging (P = 0.005) were significantly correlated with FVII antigen expression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement. Female. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Male. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 9 / analysis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. RNA, Messenger / analysis. Thromboplastin / physiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22166631.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 9001-25-6 / Factor VII; 9035-58-9 / Thromboplastin; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


90. Polido WT Jr, Lee KH, Tay KH, Wong SY, Singh R, Leong SO, Tan KC: Adult living donor liver transplantation in Singapore: the Asian centre for liver diseases and transplantation experience. Ann Acad Med Singapore; 2007 Aug;36(8):623-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult living donor liver transplantation in Singapore: the Asian centre for liver diseases and transplantation experience.
  • INTRODUCTION: Living donor liver transplantation (LDLT) has progressed dramatically in Asia due to the scarcity of cadaver donors and is increasingly performed in Singapore.
  • The authors present their experience with adult LDLT.
  • MATERIALS AND METHODS: Adult LDLTs performed at the Asian Centre for Liver Diseases and Transplantation, Singapore from 20 April 2002 until 20 March 2006 were reviewed.
  • The majority were chronic liver failure while 14% were acute.
  • The most common indication for LDLT was end-stage liver disease due to hepatitis B virus.
  • A total of 22 patients with hepatoma were transplanted and overall 1-year disease specific survival was 94.4%.
  • The mean model for end-stage liver disease (MELD) score was 17.4 +/- 9.4 (range, 6 to 40).
  • CONCLUSION: The study demonstrates that LDLT can be done safely with good results for a variety of liver diseases.
  • [MeSH-major] Liver Transplantation. Living Donors. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Female. Hospitals, Special. Humans. Male. Medical Audit. Middle Aged. Perioperative Nursing. Singapore / epidemiology. Survival Rate


91. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL: Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother; 2005 Mar-Apr;28(2):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma.
  • A phase 1 study was conducted to assess the safety and immunologic response induced by direct injection of autologous immature dendritic cells (DCs) into tumor under radiotherapy in advanced hepatoma patients.
  • Patients with advanced/metastatic stage hepatoma not suitable for surgery or transarterial embolization were enrolled.
  • Six patients showed an increased NK cell cytotoxic activity after vaccination.
  • [MeSH-major] Cancer Vaccines. Carcinoma, Hepatocellular / radiotherapy. Combined Modality Therapy. Dendritic Cells / cytology. Immunotherapy / methods. Immunotherapy, Adoptive / methods. Liver Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Autoimmune Diseases. Cohort Studies. Cytokines / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Injections, Intralesional. Interferon-gamma / metabolism. K562 Cells. Killer Cells, Natural / cytology. Male. Middle Aged. Neoplasm Metastasis. Time Factors. Tomography, X-Ray Computed. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725956.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines; 0 / alpha-Fetoproteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


92. Chiba T, Yokosuka O, Fukai K, Hirasawa Y, Tada M, Mikata R, Imazeki F, Taniguchi H, Iwama A, Miyazaki M, Ochiai T, Saisho H: Identification and investigation of methylated genes in hepatoma. Eur J Cancer; 2005 May;41(8):1185-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and investigation of methylated genes in hepatoma.
  • Previous microarray analysis demonstrated that 14 genes, including hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI2/PB) gene, showed particularly high inductions after 5-aza-2'deoxycytidine (5Aza-dC) treatment in multiple hepatoma cell lines.
  • Aberrant methylation in primary hepatoma tissues was also examined using methylation-specific polymerase chain reaction (MSP).
  • Genes for E-cadherin, collagen type I alpha 2 (COL1A2), insulin-like growth factor binding protein 2 (IGFBP2), connective tissue growth factor (CTGF) and fibronectin 1 exhibited aberrant methylation in several hepatoma cell lines.
  • In further studies of 24 primary hepatoma tissues, methylation signals for COL1A2, IGFBP2, CTGF and fibronectin 1 were detected in 13, 18, 4 and 10 patients, respectively.
  • In conclusion, aberrant methylation of COL1A2, IGFBP2, CTGF and fibronectin 1 genes were detected in hepatoma cell lines.
  • The results of MSP in hepatoma tissues suggested that some of these genes might be involved in the development or progression of hepatoma.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA Methylation. DNA, Complementary / genetics. Liver Neoplasms / genetics. Oncogenes / genetics
  • [MeSH-minor] Adult. Aged. Collagen Type I / genetics. Connective Tissue Growth Factor. CpG Islands / genetics. Female. Fibronectins / genetics. Histones / genetics. Humans. Immediate-Early Proteins / genetics. Insulin-Like Growth Factor Binding Protein 2 / genetics. Intercellular Signaling Peptides and Proteins / genetics. Male. Microarray Analysis / methods. Middle Aged. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15911243.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTGF protein, human; 0 / Collagen Type I; 0 / DNA, Complementary; 0 / Fibronectins; 0 / Histones; 0 / Immediate-Early Proteins; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / collagen type I, alpha 1 chain; 139568-91-5 / Connective Tissue Growth Factor
  •  go-up   go-down


93. Kolkhof P, Geerts A, Schäfer S, Torzewski J: Cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes. Biochem Biophys Res Commun; 2010 Mar 26;394(1):233-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show here that endogenous and plant-derived inhibitors of the Na(+)/K(+)-ATPase, i.e. the cardiac glycosides ouabain and digitoxin, inhibit IL-1beta- and IL-6-induced APP expression in human hepatoma cells and primary human hepatocytes (PHH) at nanomolar concentrations.
  • Qualified specificity of oubain for hepatocellular APP synthesis inhibition is demonstrated by lack of effectivity on IL-1beta-induced IL-6 release from primary human coronary artery smooth muscle cells.
  • [MeSH-minor] Adult. Calcium / metabolism. Cell Line, Tumor. Cells, Cultured. Digitoxin / pharmacology. Female. Humans. Interleukin-1beta / pharmacology. Interleukin-6 / pharmacology. Male. Middle Aged. Ouabain / pharmacology. Promoter Regions, Genetic / drug effects

  • Hazardous Substances Data Bank. OUABAIN .
  • Hazardous Substances Data Bank. DIGITOXIN .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20206126.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiac Glycosides; 0 / Interleukin-1beta; 0 / Interleukin-6; 5ACL011P69 / Ouabain; 9007-41-4 / C-Reactive Protein; E90NZP2L9U / Digitoxin; SY7Q814VUP / Calcium
  •  go-up   go-down


94. Asechi H, Hatano E, Nitta T, Tada M, Iwaisako K, Tamaki N, Nagata H, Narita M, Yanagida A, Ikai I, Uemoto S: Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol; 2010 Jul;37(1):89-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
  • Hepatocellular carcinoma (HCC) is known to be resistant to chemotherapy.
  • Survivin, a member of the inhibitor of apoptosis proteins, is overexpressed in most cancers but is absent in most normal adult tissue.
  • We confirmed induction of survivin expression in hepatoma in the N-diethylnitrosamine (DEN) induced rat and in the rat hepatoma cell line (K-251).
  • We examined cell proliferation after treatment with cisplatin (CDDP) in the presence and absence of siRNA or the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 to suppress survivin or PI3K/Akt, respectively.
  • Expression of survivin was observed primary in the nuclei and in the cytoplasm with immunohistochemistry.
  • Expression of survivin was also observed primarily in the nuclei and in the cytoplasm of the K-251 rat hepatoma cell line.
  • Our results indicate that survivin expression via PI3K contributes to resistance to CDDP-induced apoptosis in a rat hepatoma cell line.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma, Hepatocellular / genetics. Cisplatin / pharmacology. Drug Resistance, Neoplasm / genetics. Liver Neoplasms, Experimental / genetics. Microtubule-Associated Proteins / genetics. Phosphatidylinositol 3-Kinases / physiology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cells, Cultured. Diethylnitrosamine. Gene Expression Regulation, Neoplastic / drug effects. Male. RNA, Small Interfering / pharmacology. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514400.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Birc5 protein, rat; 0 / Microtubule-Associated Proteins; 0 / RNA, Small Interfering; 3IQ78TTX1A / Diethylnitrosamine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


95. Yndestad A, Haukeland JW, Dahl TB, Bjøro K, Gladhaug IP, Berge C, Damås JK, Haaland T, Løberg EM, Linnestad P, Birkeland K, Konopski Z, Halvorsen B, Berge RK, Aukrust P: A complex role of activin A in non-alcoholic fatty liver disease. Am J Gastroenterol; 2009 Sep;104(9):2196-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A complex role of activin A in non-alcoholic fatty liver disease.
  • OBJECTIVES: Recent studies suggest that activin A, a member of the transforming growth factor (TGF) superfamily, is involved in the pathogenesis of liver disorders.
  • We sought to explore its possible role in non-alcoholic fatty liver disease (NAFLD).
  • Gene expression was quantified in liver biopsies obtained from patients with NAFLD (n=13) and controls (n=6).
  • Effects of activin A were examined in Huh7 (human hepatoma cell line) hepatocytes.
  • Liver biopsies from NAFLD patients showed a markedly increased activin A-follistatin mRNA ratio, indicating increased hepatic activin A activity.
  • [MeSH-major] Activins / blood. Fatty Liver / blood. Follistatin / blood. Liver Cirrhosis / blood
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Gene Expression. Humans. Male. Middle Aged


96. Cheng Y, Wu J, Hertervig E, Lindgren S, Duan D, Nilsson A, Duan RD: Identification of aberrant forms of alkaline sphingomyelinase (NPP7) associated with human liver tumorigenesis. Br J Cancer; 2007 Nov 19;97(10):1441-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of aberrant forms of alkaline sphingomyelinase (NPP7) associated with human liver tumorigenesis.
  • Alkaline sphingomyelinase (alk-SMase) is expressed in the intestine and human liver.
  • The present study investigates its expression in human liver cancer.
  • In HepG2 liver cancer cells, RT-PCR identified three transcripts with 1.4, 1.2 and 0.4 kb, respectively.
  • In HepG2 cells, the alk-SMase activity is low in monolayer condition and increased with cell polarisation.
  • Coexistence of 1.4 and 1.2 kb forms was also identified in one hepatoma biopsy.
  • GenBank search identified a cDNA clone from human liver tumour, which codes a protein containing full length of alk-SMase plus a 73-amino-acid tag at the N terminus.
  • We also analysed human liver biopsy samples and found relatively low alk-SMase activity in diseases with increased risk of liver tumorigenesis.
  • [MeSH-major] Alternative Splicing / genetics. Liver Neoplasms / enzymology. Sphingomyelin Phosphodiesterase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amino Acid Sequence. Animals. Base Sequence. COS Cells. Cell Line, Tumor. Cells, Cultured. Cercopithecus aethiops. DNA Mutational Analysis. DNA, Complementary / genetics. Enzyme Activation / genetics. Exons. Female. Gene Expression Regulation, Enzymologic / genetics. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction / methods. Risk Factors. Transcription, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Jun 15;97(12):3036-43 [12784339.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):889-93 [12671884.001]
  • [Cites] Dig Dis Sci. 2003 Jun;48(6):1094-101 [12822868.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Oct;129(10):577-82 [12920578.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38528-36 [12885774.001]
  • [Cites] Gut. 2004 Jun;53(6):877-83 [15138217.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1327-33 [15016655.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):604-16 [15286740.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G967-73 [15205117.001]
  • [Cites] Biochim Biophys Acta. 1969 Mar 4;176(2):339-47 [5775951.001]
  • [Cites] Methods Enzymol. 1975;35:533-41 [164606.001]
  • [Cites] Brain Res. 1979 Jun 8;168(3):543-51 [219938.001]
  • [Cites] Biochemistry. 1988 Feb 9;27(3):1067-74 [2835076.001]
  • [Cites] J Nutr. 1995 Jun;125(6 Suppl):1677S-1682S [7782925.001]
  • [Cites] Biochim Biophys Acta. 1996 Mar 29;1300(1):42-8 [8608160.001]
  • [Cites] Dig Dis Sci. 1996 Sep;41(9):1801-6 [8794797.001]
  • [Cites] Adv Exp Med Biol. 1996;392:279-96 [8850624.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Jan;142(1):208-25 [9007051.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):448-53 [9028353.001]
  • [Cites] Hepatology. 1997 Oct;26(4):823-30 [9328299.001]
  • [Cites] Dig Dis Sci. 1998 Jan;43(1):26-32 [9508530.001]
  • [Cites] J Lipid Res. 1999 Mar;40(3):533-42 [10064742.001]
  • [Cites] Br J Cancer. 1999 Sep;81(2):232-6 [10496347.001]
  • [Cites] Scand J Gastroenterol. 1999 Sep;34(9):915-20 [10522612.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):503-5 [15455343.001]
  • [Cites] Biochem J. 2005 Feb 15;386(Pt 1):153-60 [15458386.001]
  • [Cites] Biochim Biophys Acta. 2005 Feb 21;1687(1-3):94-102 [15708357.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):856-62 [15824156.001]
  • [Cites] Trends Biochem Sci. 2005 Oct;30(10):542-50 [16125936.001]
  • [Cites] J Lipid Res. 2006 Jan;47(1):154-71 [16251722.001]
  • [Cites] Biochem J. 2006 Feb 15;394(Pt 1):299-308 [16255717.001]
  • [Cites] Semin Liver Dis. 2006 Feb;26(1):31-41 [16496231.001]
  • [Cites] Cancer Lett. 2006 Apr 8;235(1):141-6 [16290921.001]
  • [Cites] Biochim Biophys Acta. 2006 Mar;1761(3):281-91 [16631405.001]
  • [Cites] Biochemistry. 2006 Aug 15;45(32):9788-803 [16893180.001]
  • [Cites] Semin Liver Dis. 2006 Feb;26(1):42-51 [16496232.001]
  • [Cites] Methods Enzymol. 2000;311:276-86 [10563333.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5016-23 [11431335.001]
  • [Cites] Inflamm Bowel Dis. 2002 Jul;8(4):258-63 [12131609.001]
  • [Cites] Liver. 2002 Oct;22(5):394-403 [12390475.001]
  • [Cites] Carcinogenesis. 2002 Dec;23(12):2087-93 [12507932.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 30;1585(2-3):114-25 [12531544.001]
  • [Cites] Carcinogenesis. 2003 Jun;24(6):1077-83 [12807752.001]
  • (PMID = 17923876.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AK126250
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; EC 3.1.4.12 / Sphingomyelin Phosphodiesterase
  • [Other-IDs] NLM/ PMC2360232
  •  go-up   go-down


97. Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J, Zhang FC, Cui Q, Dong Y: Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford); 2010 Mar;49(3):571-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort.
  • OBJECTIVES: To evaluate the incidence of malignancies in a cohort of Chinese patients with primary Sjögren's syndrome (pSS) and to identify the risk factors of malignancy in pSS patients.
  • Different types of malignancy were observed including eight lymphomas, two myeloid myelomas and 19 solid tumours, which consisted of invasive thymoma, breast cancer, lung cancer, gastrointestinal adenocarcinoma, hepatoma, squamous cell carcinoma of tongue, uterine cervix cancer, renal carcinoma, thyroid carcinoma and mucoepidermoid carcinoma of parotid gland.
  • CONCLUSIONS: The current study confirms the increased incidence of lymphoma in Chinese patients with pSS, with the majority of B-cell non-Hodgkin's lymphoma.
  • [MeSH-minor] Adult. China / epidemiology. Epidemiologic Methods. Female. Humans. Lymphoma / epidemiology. Lymphoma / etiology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040528.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


98. Dannenberg LO, Edenberg HJ: Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics; 2006 Jul 19;7:181
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation.
  • We hypothesize that many genes in the human hepatoma cell line HepG2 are regulated by DNA methylation and histone deacetylation.
  • Treatment with 5-aza-2'-deoxycytidine (5-aza-dC) to inhibit DNA methylation with and/or Trichostatin A (TSA) to inhibit histone deacetylation should allow us to identify genes that are regulated epigenetically in hepatoma cells.
  • Genes involved in liver processes such as xenobiotic metabolism (CYP3A4, CYP3A5, and CYP3A7) and steroid biosynthesis (CYP17A1 and CYP19A1), and genes encoding CCAAT element-binding proteins (C/EBPalpha, C/EBPbeta, and C/EBPgamma) were affected by 5-aza-dC or the combination.
  • Many of the genes that fall within these groups are also expressed in the developing fetal liver and adult liver.
  • CONCLUSION: Epigenetics play a role in regulating the expression of several genes involved in essential liver processes such as xenobiotic metabolism and steroid biosynthesis in HepG2 cells.
  • Many genes whose expression is normally silenced in these hepatoma cells were re-expressed by 5-aza-dC treatment.
  • DNA methylation may be a factor in restricting the expression of fetal genes during liver development and in shutting down expression in hepatoma cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):17174-9 [2211619.001]
  • [Cites] Cell. 1991 Nov 1;67(3):569-79 [1934061.001]
  • [Cites] Cell. 1993 Jan 15;72(1):73-84 [8422685.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8219-23 [8367486.001]
  • [Cites] Curr Opin Genet Dev. 1999 Apr;9(2):158-63 [10322130.001]
  • [Cites] EMBO J. 1994 Feb 15;13(4):851-60 [7906646.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11797-801 [7527544.001]
  • [Cites] Nat Genet. 1995 Aug;10(4):383-93 [7670487.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4525-30 [7553621.001]
  • [Cites] Annu Rev Genet. 1997;31:493-525 [9442905.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4353-65 [9834242.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3693-702 [9851976.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Curr Opin Genet Dev. 1999 Apr;9(2):148-51 [10322131.001]
  • [Cites] Genes Dev. 1999 Sep 15;13(18):2339-52 [10500090.001]
  • [Cites] J Hepatol. 2004 Nov;41(5):790-8 [15519652.001]
  • [Cites] BMC Genomics. 2003;4(1):4 [12594857.001]
  • [Cites] Mol Biol Rep. 2005 Sep;32(3):141-7 [16172914.001]
  • [Cites] Carcinogenesis. 2005 Nov;26(11):1856-67 [15958521.001]
  • [Cites] BMC Bioinformatics. 2006;7:49 [16448562.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Jun;30(6):928-37 [16737450.001]
  • [Cites] J Biol Chem. 1997 Dec 19;272(51):32260-6 [9405430.001]
  • [Cites] Gene. 1999 Nov 15;240(1):1-12 [10564807.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):1899-910 [10688638.001]
  • [Cites] Nature. 2000 May 25;405(6785):482-5 [10839546.001]
  • [Cites] Trends Biochem Sci. 2000 Dec;25(12):619-23 [11116189.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):383-91 [11279519.001]
  • [Cites] J Cell Biochem. 2001;82(3):357-70 [11500913.001]
  • [Cites] Mol Cell. 2001 Sep;8(3):719-25 [11583633.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):412-7 [11726928.001]
  • [Cites] J Urol. 2002 Jan;167(1):335-8 [11743352.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] EMBO J. 1983;2(3):317-24 [11894944.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2336-45 [11994385.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Methods. 2002 Jun;27(2):150-5 [12095274.001]
  • [Cites] EMBO J. 2002 Sep 2;21(17):4632-40 [12198165.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):586-90 [12629040.001]
  • [Cites] N Engl J Med. 2003 Mar 20;348(12):1134-49 [12646671.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2003 May;3(3):187-99 [12769777.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):599-609 [14992728.001]
  • [Cites] Biochim Biophys Acta. 1970 Nov 11;220(2):307-16 [5487884.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1211-6 [7566983.001]
  • [Cites] Nucleic Acids Res. 1995 Nov 11;23(21):4371-7 [7501458.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2463-7 [8653676.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2508-18 [8665858.001]
  • [Cites] Hum Mol Genet. 1996 Jul;5(7):933-43 [8817327.001]
  • [Cites] Hum Mol Genet. 1996 Nov;5(11):1801-7 [8923009.001]
  • [Cites] Genes Dev. 1997 Aug 15;11(16):2124-36 [9284051.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Trends Genet. 1997 Nov;13(11):444-9 [9385841.001]
  • [Cites] J Biol Chem. 1972 Nov 25;247(22):7365-73 [4674086.001]
  • [Cites] Biochemistry. 1973 Feb 27;12(5):783-91 [4568767.001]
  • [Cites] J Biol Chem. 1975 Jul 10;250(13):4856-63 [168194.001]
  • [Cites] Somatic Cell Genet. 1979 Nov;5(6):719-38 [545721.001]
  • [Cites] Science. 1980 Jul 25;209(4455):497-9 [6248960.001]
  • [Cites] Nature. 1979 Dec 6;282(5739):615-6 [233137.001]
  • [Cites] J Biol Chem. 1982 Feb 25;257(4):2041-8 [6173384.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):6993-7 [6209710.001]
  • [Cites] J Steroid Biochem. 1986 Nov;25(5B):749-57 [2433505.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3076-83 [2444874.001]
  • [Cites] DNA. 1987 Oct;6(5):439-48 [3500022.001]
  • [Cites] Arch Biochem Biophys. 1989 Jan;268(1):144-51 [2492179.001]
  • [Cites] In Vitro Cell Dev Biol. 1989 Mar;25(3 Pt 1):267-75 [2466823.001]
  • [Cites] Biochem J. 1990 Jan 1;265(1):23-38 [2405837.001]
  • [Cites] Cell. 1990 Aug 10;62(3):503-14 [1974172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6117-21 [2385586.001]
  • (PMID = 16854234.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R37 AA006460; United States / NIAAA NIH HHS / AA / R37AA06460
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histones; 0 / Hydroxamic Acids; 3X2S926L3Z / trichostatin A; EC 3.5.1.98 / Histone Deacetylases; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC1574318
  •  go-up   go-down


99. Dong ZZ, Yao DF, Yu HB, Gu WJ, Shen YC, Li YM, Wang YL, Shen JJ: [Dynamic expression and quantitative analysis of hepatic nuclear factor-kappa B and its gene during the development of hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi; 2008 Sep;16(9):669-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dynamic expression and quantitative analysis of hepatic nuclear factor-kappa B and its gene during the development of hepatocellular carcinoma].
  • OBJECTIVE: To investigate the kinetic expression and alteration of nuclear transcription factor-kappa B (NF-kappaB) and its gene in hepatocellular carcinoma (HCC) development.
  • METHODS: A hepatoma model was established with N-(2-fluorenyl) acetamide (2-FAA) using male SD rats.
  • The liver specimens from HCC patients were collected by self-control method.
  • RESULTS: Hepatocytes showed vacuole-like denaturation, atypical hyperplasia, and transformation into highly differentiated cancerous hepatocytes with increasing tendencies of liver NF-kappaB and NF-kappaB mRNA expressions.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms, Experimental / metabolism. NF-kappa B / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Female. Humans. Male. Middle Aged. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18822207.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NF-kappa B
  •  go-up   go-down


100. Hellerbrand C, Bataille F, Schlegel J, Hartmann A, Mühlbauer M, Schölmerich J, Büttner R, Hofstädter F, Bosserhoff AK: In situ expression patterns of melanoma inhibitory activity 2 in healthy and diseased livers. Liver Int; 2005 Apr;25(2):357-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed liver tissue of patients with chronic hepatitis C (HepC) infection and hepatocellular carcinoma (HCC) as well as a human multi-tissue array, primary human hepatocytes and the hepatoma cell-lines HepG2, Hep3B and PLC by immunohistochemical staining and quantitative RT-PCR.
  • RESULTS: Hepatocytes were confirmed as the exclusive cellular source of MIA2 expression, with a granular, cytoplasmatic staining pattern without enhancement at the cell membrane.
  • In contrast, only low MIA2 expression levels were detected in most HCC and hepatoma cell lines.
  • Interestingly, both in HCC and liver tissues of patients with HepC we found a correlation of MIA2 and alpha-sma expression.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Hepatitis, Chronic / pathology. Liver Cirrhosis / pathology. Liver Neoplasms / pathology. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Base Sequence. Biomarkers / analysis. Biopsy, Needle. Case-Control Studies. Extracellular Matrix Proteins. Female. Gene Expression Regulation, Neoplastic. Hepatocytes / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Molecular Sequence Data. Prognosis. RNA, Neoplasm / analysis. RNA, Viral / analysis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Tissue Culture Techniques

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2005
  • (PMID = 15780062.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Extracellular Matrix Proteins; 0 / MIA protein, human; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / RNA, Viral
  •  go-up   go-down






Advertisement